Immuron Limited (IMRN) 20-F 31 Oct 18 2018 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Jun. 30, 2018shares
Document And Entity Information
Entity Registrant Name	Immuron Ltd
Entity Central Index Key	1,660,046
Document Type	20-F
Trading Symbol	IMC
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	142,778,206
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,018

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Revenue
Operating Revenue	$ 1,842,909	$ 1,396,197	$ 1,001,077
Total Operating Revenue	1,842,909	1,396,197	1,001,077
Cost of Goods Sold	(418,693)	(337,546)	(301,435)
Gross Profit	1,424,216	1,058,651	699,642
Direct Selling Costs
Sales and Marketing Costs	(282,241)	(407,751)	(133,781)
Freight Costs	(169,458)	(135,377)	(134,967)
Total Gross Profit less Direct Selling Costs	972,517	515,523	430,894
Other Income	1,850,401	1,614,373	1,539,015
Expenses
Consulting, Employee and Director	(1,384,298)	(1,689,521)	(2,840,037)
Other Corporate Administration	(1,336,516)	(1,381,809)	(1,320,570)
Depreciation	(5,047)	(4,922)	(3,892)
Finance Costs	(18,857)	(24,483)	(341,600)
Impairment of Inventory	(163,600)	(136,494)	(4,176)
Marketing and Promotion	(370,699)	(789,608)	(487,591)
Research and Development	(2,257,224)	(4,630,674)	(3,623,961)
Travel and Entertainment	(297,606)	(276,539)	(416,849)
Loss Before Income Tax	(3,010,929)	(6,804,154)	(7,068,767)
Income Tax Expense
Loss for the Period	(3,010,929)	(6,804,154)	(7,068,767)
Other Comprehensive Income (Loss)	(79,599)	40,017	8,846
Total Comprehensive Loss for the Period	$ (3,090,528)	$ (6,764,137)	$ (7,059,921)
Basic/Diluted Loss per Share (in cents per share)	$ 2.300	$ 6.400	$ 9.248

Consolidated Statement of Finan

Consolidated Statement of Financial Position - AUD ($)		Jun. 30, 2018	Jun. 30, 2017
Current Assets
Cash and cash equivalents		$ 4,727,430	$ 3,994,924
Trade and other receivables		1,683,305	1,768,237
Inventories		497,902	2,336,127
Other		141,800	168,366
Total Current Assets		7,050,437	8,267,654
Non-Current Assets
Plant and equipment		20,384	18,837
Inventories		2,171,867
Total Non-Current Assets		2,192,251	18,837
TOTAL ASSETS		9,242,688	8,286,491
Current liabilities
Trade and other payables		689,326	1,290,389
Borrowings	[1]		139,864
Convertible notes			226,000
Employee benefit obligations		114,012	36,173
Deferred Revenue	[2]		19,139
Total Current Liabilities		803,338	1,711,565
TOTAL LIABILITIES		803,338	1,711,565
NET ASSETS		8,439,350	6,574,926
EQUITY
Issued capital		58,372,043	53,632,995
Reserves		2,606,722	2,470,417
Accumulated losses		(52,539,415)	(49,528,486)
TOTAL EQUITY		$ 8,439,350	$ 6,574,926
[1]	Borrowings: The Company has financed A$162,457 for its insurance policies during the year ended June 30, 2017. Principal and interest (A$8,561) is to be repaid monthly by Immuron over a 11-month term. During the financial year 2018, the outstanding borrowings were repaid by the Company.
[2]	Deferred Revenue: This amount represents amounts billed by the Company for undelivered goods.

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - AUD ($)	Issued capital [Member]	Reserves [Member]	AccumulatedLosses	Total
Balance as at beginning at Jun. 30, 2015	$ 40,335,347	$ 548,065	$ (36,072,810)	$ 4,810,602
Changes in equity [abstract]
Loss after income tax expense for the year			(7,068,767)	(7,068,767)
Other comprehensive income for the period		8,846		8,846
Total comprehensive loss for the period		8,846	(7,068,767)	(7,059,921)
Transactions with owners in their capacity as owners
Options/warrants issued/expensed		1,891,875		1,891,875
Lapse or exercise of share options		(320,220)	320,220
Shares issued, net of costs	1,586,629			1,586,629
Share to be issued	4,511,378			4,511,378
Treasury shares	(800,000)			(800,000)
Balance as at end at Jun. 30, 2016	45,633,354	2,128,566	(42,821,357)	4,940,563
Changes in equity [abstract]
Loss after income tax expense for the year			(6,804,154)	(6,804,154)
Other comprehensive income for the period		40,017		40,017
Total comprehensive loss for the period		40,017	(6,804,154)	(6,764,137)
Transactions with owners in their capacity as owners
Options/warrants issued/expensed		470,734		470,734
Lapse or exercise of share options	71,875	(168,900)	97,025
Shares issued, net of costs	7,927,766			7,927,766
Balance as at end at Jun. 30, 2017	53,632,995	2,470,417	(49,528,486)	6,574,926
Changes in equity [abstract]
Loss after income tax expense for the year			(3,010,929)	(3,010,929)
Other comprehensive income for the period		(79,599)		(79,599)
Total comprehensive loss for the period		(79,599)	(3,010,929)	(3,090,528)
Transactions with owners in their capacity as owners
Options/warrants issued/expensed		215,904		215,904
Shares issued, net of costs	4,739,048			4,739,048
Balance as at end at Jun. 30, 2018	$ 58,372,043	$ 2,606,722	$ (52,539,415)	$ 8,439,350

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Cash flows Related to Operating Activities
Receipts from customers	$ 1,601,619	$ 1,413,676	$ 1,114,596
Payments to suppliers and employees	(7,262,348)	(9,971,142)	(7,710,997)
Interest received	1,278	8,386	12,165
Interest and other costs of finance paid	(24,199)	(97,051)	(43,863)
Other - R&D Tax Concession Refund	2,156,206	1,615,043	1,469,763
Net Cash Flows Used In Operating Activities	(3,527,444)	(7,031,088)	(5,158,336)
Cash Flows Related to Investing Activities
Payment for purchases of plant and equipment	(6,594)	(5,696)	(2,441)
Net Cash Flows Used In Investing Activities	(6,594)	(5,696)	(2,441)
Cash Flows Related to Financing Activities
Proceeds from issues of securities	5,315,810	12,525,067	2,482,861
Capital raising costs	(576,762)	(2,132,422)	(20,299)
Proceeds from borrowings	500,000	500,000	2,950,000
Repayment of borrowings	(865,864)	(2,191,593)	(1,077,220)
Net Cash Flows From/(Used In) Financing Activities	4,373,184	8,701,052	4,335,342
Net increase/(decrease) in cash and cash equivalents	839,146	1,664,268	(825,435)
Cash and cash equivalents at the beginning of the year	3,994,924	2,290,639	3,116,074
Effects of exchange rate changes on cash and cash equivalents	(106,640)	40,017
Cash and Cash Equivalents at the End of the Year	$ 4,727,430	$ 3,994,924	$ 2,290,639

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2018
Summary Of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 1. Summary of Significant Accounting Policies Corporate Information The consolidated financial report of Immuron Limited (‘the Company’) for the year ended 30 June 2018, 2017 and 2016 was authorized for issue in accordance with a resolution of the Directors on October 29, 2018. Immuron Limited is a listed public company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange (ASX) and NASDAQ. The principal activity of the Company is a product development driven biopharmaceutical Company focused on the research and development of polyclonal antibodies for the treatment and prevention of major diseases. Basis of Preparation The financial report is a general-purpose financial report, which has been prepared in accordance with the requirements of International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), required for a for-profit entity. The financial report has been prepared on an accruals basis and is based primarily on historical costs. The financial report is presented in Australian dollars, which is the Company’s functional and presentation currency. All values are rounded to the nearest dollar unless otherwise stated. Management is required to make judgements, estimates and assumptions about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstance, the results of which form the basis of making the judgements. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. Accounting policies are selected and applied in a manner which ensures that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the underlying transactions or other events is reported. Statement of Compliance This financial report complies with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). New, revised or amending Accounting Standards and Interpretations adopted All accounting policies adopted are consistent with the most recent Annual Financial Report for the year ended 30 June 2018. The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretation issued by the International Accounting Standards Board (‘IASB’) that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity. International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (‘IASB’) that have recently been issued or amended but are not yet effective and have not been adopted by the Company for the annual reporting period ending 30 June 2018 are outlined in the table below. Standard Mandatory date for annual reporting periods (beginning on or after) Reporting period standard adopted by the company IFRS 9 Financial Instruments and related standards 1 January 2018 1 July 2018 IFRS 15 Revenue from Contracts with Customers 1 January 2018 1 July 2018 IFRS 2 – Amendments to Share based 1 January 2018 1 July 2018 IFRS 16 - Leases 1 January 2019 1 July 2019 Management has performed a detailed assessment on the impact of IFRS 15, IFRS 9 and IFRS 16 on the recognition of revenue and concluded that there would be no material difference to how revenue has been recognized under the prevailing accounting standard. Certain new accounting standards and interpretations have been published that are not mandatory for 30 June 2018 reporting periods and have not been early adopted by the Company. There are no other standards that are not yet effective and that would be expected to have a material impact on the Group in the current or future reporting periods and on foreseeable future transactions. The following is a summary of the material accounting policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated. (a) Basis of Consolidation The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries) referred to as ‘the Group’ in the financial statements. Control is achieved where the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases. A list of controlled entities is contained in Note 11 to the financial statements. All controlled entities have a 30 June financial year-end. All intra-group transactions, balances, income and expenses are eliminated in full on consolidation. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with those policies applied by the parent entity. Subsidiaries are accounted for at cost in the parent entity. The results of subsidiaries acquired or disposed of during the year are included in profit or loss from the effective date of acquisition or up to the effective date of disposal, as appropriate. (b) Segment Reporting The Company determines and presents operating segments using the ‘management approach’ where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Maker (‘CODM’). The CODM is responsible for the allocation of resources to operating segments and assessing their performance and provide the strategic direction and management oversight of the day to day activities of the entity in terms of monitoring results, providing approval for research and development expenditure decisions and challenging and approving strategic planning for the business. (c) Foreign Currency Translation Functional and Presentation Currency Items included in the financial statements are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The financial statements are presented in Australian dollars, which is the Company’s functional and presentation currency. Transactions and Balances Transactions in foreign currencies are translated into the functional currency using the rates of exchange ruling at the date of each transaction. At reporting date, amounts outstanding in foreign currencies are translated into the functional currency using the rate of exchange ruling at the end of the financial year. Refer to Note 3 for the foreign currency gains and losses recognized during the periods. Foreign exchange gains and losses that relate to borrowings are presented in the statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the statement of profit or loss and other comprehensive income on a net basis within Corporate Administration Costs. Immuron Inc., a subsidiary of the Group, has USD as its functional currency. Accordingly, this entity’s statement of comprehensive income and statement of financial position balances have been translated to the Group’s presentation currency (which is AUD$) at the reporting date. A gain arising from this translation of AUD$79,599 (2017: AUD$40,017) are recognized as Other Comprehensive Income for the year. (d) Revenue Recognition Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties. The Company recognizes revenue when the amount of the revenue can be reliably measured, it is probable that the future economic benefits will flow to the entity and specific criteria have been met for each of the activities as described below. The amount of the revenue is not considered to be reliably measured until all contingencies relating to the sale have been resolved. The following specific revenue criteria must be met before revenue is recognized: Sale of Goods and services Significant risks and rewards of ownership of goods has passed to the buyer and an invoice for the goods or services is issued Interest Interest income is recognized using the effective interest rate method R & D Tax Refund Income is recognized in the year the research and development expenses were incurred We engaged experienced advisors (KPMG) to determine and evaluate the advanced findings of the R&D activities, which includes determining and evaluating the eligibility of R&D related expenditure to support our submission of the R&D Tax refund claim. As at 30 June 2018, the recorded income in relation to the R&D was A$ 1,849,123 and the receivable for financial period 2018 was accrued in the statement of financial position was A$ 1,191,029. (e) Government Grants Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received, and the Company will comply with all attached conditions. Government grants relating to costs to be incurred are deferred or accrued such that they are recognized in the statement of profit or loss and other comprehensive income over the period necessary to match them with the costs that they are intended to compensate. (f) Income Tax The income tax expense or revenue for the period is the tax payable or tax rebate receivable on the current period’s taxable income adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax base of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses. Deferred income tax is provided in full, using the liability method on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither the accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax is realized or the deferred income tax liability is settled. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Current and deferred tax balances attributable to amounts recognized directly in equity are also recognized directly in equity. (g) Impairment of Assets Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use. (h) Cash and Cash Equivalents For presentation purposes, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short- term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. (i) Trade Receivables Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest rate method, less provision for impairment. Trade receivables are due for settlement no more than 30 days from the date of recognition. Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off. A provision for impairment of trade receivables is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of receivables. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganization and default or delinquency in payment (more than 30 days overdue) are considered indicators that the trade receivable is impaired. The amount of the provision is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. Cash flows relating to short term receivables are not discounted if the effect of discounting is immaterial. The amount of the provision is recognized in the statement of profit or loss and other comprehensive income. (j) Inventories Raw materials, work in progress and finished goods are stated at the lower of cost and net realizable value. Cost comprises direct materials, freight and import duty. The Company classifies inventory as a current asset for amounts it expects to sell or consume within its normal operating cycle. Costs are assigned to individual items of finished goods inventory on basis of weighted average costs. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. (k) Plant & Equipment Plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Repairs and maintenance are charged to the statement of profit or loss and other comprehensive income during the financial period in which they are incurred. Depreciation on assets is calculated using the straight-line method to allocate their cost, net of their residual values, over their estimated useful lives, as follows: - Plant & Equipment (3 - 15 years) - Computer Equipment (2 - 4 years) - Furniture & Fittings (3 - 15 years) The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, annually. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount (Note 1(g)). Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in the statement of profit or loss and other comprehensive income. (l) Intangible Assets (i) Research & Development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the statement of profit or loss and other comprehensive income as an expense when it is incurred. Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalized if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits and adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the statement of profit or loss and other comprehensive income as an expense as incurred. (m) Trade and Other Payables These amounts represent liabilities for goods and services provided to the entity prior to the end of the financial year and which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade payables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest rate method. (n) Employee Benefits (i) Short-term obligations Liabilities for wages and salaries, annual leave and long service leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. (ii) Other long-term employee benefits obligations The liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. The obligations are presented as current liabilities in the Statement of financial position if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur. (iii) Retirement benefit obligations Contributions to the defined contribution superannuation funds are recognized as an expense as they become payable. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. (iv) Share-based payments Share-based compensation benefits may be provided through the issue of fully paid ordinary shares under the Immuron Employee Share and Option Plan (“ESOP”). Options are also granted to employees and consultants in accordance with the terms of their respective employment and consultancy agreements. Any options granted are made in accordance with the terms of the Company’s ESOP. The fair value of options granted under employment and consultancy agreements are recognized as an employee benefit expense with a corresponding increase in equity. The fair value is measured at grant date and recognized over the period during which the employees become unconditionally entitled to the options. The fair value at grant date is determined using a Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the vesting and performance criteria, the impact of dilution, the non-tradeable nature of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the option. The fair value of the options granted excludes the impact of any non-market vesting conditions (for example, profitability and sales growth targets). Non-market vesting conditions are included in assumptions about the number of options that are expected to become exercisable. At each reporting date, the entity revises its estimate of the number of options that are expected to become exercisable. The employee benefit expense recognized each period takes into account the most recent estimate. The impact of the revision to original estimates, if any, is recognized in the statement of profit or loss and other comprehensive in come with a corresponding adjustment to equity. Upon the exercise of options, the balance of the share-based payments reserve relating to those options is transferred to contributed equity. (v) Termination benefits Termination benefits are payable when employment is terminated before the normal retirement date, or when an employee accepts voluntary redundancy in exchange for these benefits. The Company recognises termination benefits when it is demonstrably committed to either terminating the employment of current employees according to a detailed formal plan without possibility of withdrawal or providing termination benefits as a result of an offer made to encourage voluntary redundancy. Benefits falling due more than 12 months after reporting date are discounted to present value. (o) Interest Bearing Loans and Borrowings Generally, loans and borrowings are initially recognized at cost, being the fair value of the consideration received net of issue costs associated with the borrowing. After initial recognition, interest bearing loans and borrowings are subsequently measured at amortized cost using the effective interest method. Amortized cost is calculated by taking into account any issue costs and any discount or premium on settlement. The component of the convertible notes that were issued in connection with the February 2016 financing arrangement that exhibits characteristics of a liability is recognised as a liability in the statement of financial position. On the date of issuance and each subsequent reporting period, the Company records the entire hybrid instrument as measured at fair value through profit and loss as the embedded derivative does significantly modify the cash flows under the contract. The associated transaction costs have also been expensed as incurred and are recorded as Finance costs in the Statement of Profit or Loss and Other Comprehensive Income. Fair Value of Convertible Notes The convertible notes were measured and disclosed as a level 3 instrument, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, as defined below: ● Level 1: Quoted price (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date ● Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset and liability, either directly or indirectly ● Level 3: Unobservable inputs for the asset or liability No transfers between the levels of the fair value hierarchy occurred during the current year. (p) Contributed Equity Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction from the proceeds. (q) Earnings per Share (i) Basic earnings per share Basic earnings per share is calculated by dividing the profit or loss attributable to equity holders of the Company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the full year, adjusted for bonus elements in ordinary shares issued during the full year. (ii) Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. (r) Goods and Services Tax (GST) Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST recoverable or payable. The net amount of GST recoverable from, or payable to, the taxation authorities is included with other receivable or payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flow arising from investing or financing activities which are recoverable for, or payable to, the taxation authorities are presented as operating cash flow. (s) Leases Leases in which a significant portion of the risk and reward of ownership are not transferred to the Company as lessee are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the statement of profit or loss and other comprehensive income on a straight-line basis over the period of the lease. Critical Accounting Estimates and Judgments Management evaluates estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both internally and externally. (i) Share-based Payments The value attributed to share options and remunerations shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the value of volatility of the price of the underlying shares. Refer to note 19 for more details. (ii) Impairment of Inventories The provision for impairment of inventories assessment requires a degree of estimation and judgment. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventories and in particular the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. (iii) Provision for employee benefits Provision for employee benefits represents amounts accrued for annual leave and long service leave. The current portion for this provision includes the total amount accrued for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the required period of service. (iv) R&D tax incentive The Group’s research and development activities are eligible under an Australian Government tax incentive for eligible expenditure from 1 July 2011. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. For the year ended 30 June 2018 the Group has recorded in other income of $1,849,123 (2017: $1,575,315) to recognize this amount which relates to this financial year. (v) Inventory split The Company’s policy is to reassess the classification of inventory on a periodic basis to determine if the inventory have a longer shelf-life and to assess whether there exists an alternative market for the Colostrum powder (which remains a majority of the inventory). During the current financial period, management have performed an assessment on its raw materials and its utilization within 12 months from reporting date and have determined $198,585 of raw materials relating to Colostrum expected to be consumed with 12 months and remaining balance of $2,171,867 expected to be consumed after 12 months from reporting date. During the year ended June 30, 2018, management determined that a portion of its inventory should be reclassified on a prospective basis as a noncurrent asset as a result of a strategic decision made by management in the intended use of its inventory. The Company decided to terminate all plans to sell the colostrum powder to secondary markets as a result of the continued scientific evidence supporting an extended shelf life. The extended shelf life provides the Company with the assurance that colostrum will be consumed through the production of its current Travelan and Protectyn products throughout future reporting periods. (vi) Fair value measurement hierarchy The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections where applicable. The fair value of the convertible notes classified as level 3 are determined by the use of valuation model. These include discounted cash flow analysis and the use of observable inputs that required significant adjustments based on unobservable inputs. As at June 30, 2017, management has assessed the terms of the convertible notes and determined that in their view the fair value of the debt component is equal to the proceeds such that there is no residual amount to be allocated to an equity component. In making this determination, management is of the view that the value of the consideration received, net of costs, provided reliable evidence of the fair value of the debt component of the convertible notes. Fair value has been determined by the income approach based on a discounted cash flow analysis, with the most significant inputs being the discount rate that reflects the investors credit risk. A slight increase or decrease in the discount rate used would not be material to the financial statements. Reconciliation of level 3 fair value measurements: Convertible notes/debentures AUD$ Balance at 30 June 2016 1,128,117 - Issue — - Change in fair value (*) — - Repayments (902,117 ) Balance at 30 June 2017 (Note 13) 226,000 (*) These amounts are recorded in the Finance Costs on the Statement of Profit or Loss and Other Comprehensive Income. (t) Comparatives Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to reclassify the employee benefit obligations within the Consolidated Statements Financial Position for fiscal year ended September 30, 2017 to seek consistent presentation with the current financial period

Revenue and other income

Revenue and other income	12 Months Ended
	Jun. 30, 2018
Revenue And Other Income
Revenue and other income	Note 2. Revenue and other income 30 June 2018 30 June 2017 30 June 2016 AUD$ AUD$ AUD$ Revenue Revenue from Operating Activities Sale of goods 1,842,909 1,396,197 1,001,077 Total Revenue from Operating Activities 1,842,909 1,396,197 1,001,077 Other Income Other income 40 30,672 14,010 Interest income 1,238 8,386 12,165 R&D tax concession refund 1,849,123 1,575,315 1,512,840 Other Income from Non-Operating Activities 1,850,401 1,614,373 1,539,015 Total Revenue and Other Income 3,693,310 3,010,570 2,540,092

Expenses

Expenses	12 Months Ended
	Jun. 30, 2018
Expenses Abstract
Expenses	Note 3. Expenses 30 June 2018 30 June 2017 30 June 2016 Expenses a) Consulting, Employee and Director Expenses Consulting expenses — — 46,775 Wages and salaries expenses 885,197 905,819 956,737 Superannuation and other employee related expenses 153,795 39,664 32,537 Director expenses 285,331 221,373 197,713 Share- based payments 59,975 522,665 1,606,275 Total Consulting, Employee and Director Expenses 1,384,298 1,689,521 2,840,037 b) Corporate Administrative Costs Audit and accounting fees 222,973 146,007 62,825 Insurances 277,888 150,502 100,609 Foreign exchange (gain) / losses (258,767 ) 238,985 217,904 Corporate administration costs 1,094,422 846,315 939,232 Total Corporate Administrative Costs 1,336,516 1,381,809 1,320,570

Income Tax Benefit

Income Tax Benefit	12 Months Ended
	Jun. 30, 2018
Income Tax Benefit
Income Tax Benefit	Note 4. Income Tax Benefit The Company has approximately tax losses of A$ 35,299,886 (2017: A$ 30,138,000), representing a Deferred Tax Asset of A$ 9,707,469 (at 27.5%) (2017: A$ 8,287,950) (at 27.5%) that has not been recognized in the Financial Statements, refer to Note 1(f). Numerical reconciliation of income tax expense to prima facie tax payable 30 June 2018 AUD$ Profit from continuing operations before income tax expense (3,010,929 ) Tax at the Australian tax rate of 27.5% (2017 - 27.5%, 2016 – 30%) (828,005 ) Tax effect of amounts which are not deductible (taxable) in calculating taxable income: Non-deductible amounts associated with R&D rebates (508,509 ) Non-allowable expenses 796,398 Deferred tax assets relating to tax losses not recognized 540,116 Income tax expense —

Key Management Personnel Compen

Key Management Personnel Compensation	12 Months Ended
	Jun. 30, 2018
Key Management Personnel Compensation
Key Management Personnel Compensation	Note 5. Key Management Personnel Compensation This note details the nature and amount of remuneration for each Director of Immuron Limited, and for the Key Management Personnel. The Directors of Immuron Limited during the year ended 30 June 2018 were: The following persons held office as Directors of Immuron Limited during the financial year: Dr. Roger Aston, Independent non-executive chairman Mr. Peter Anastasiou, Executive vice chairman Mr. Daniel Pollock, Independent non-executive director Mr. Stephen Anastasiou, Independent non-executive director Prof. Ravi Savarirayan, Independent non-executive director (appointed April 7, 2017) Mr. Richard J Berman, Independent non-executive director (appointed July 1, 2018) The following persons held office as Key Management Personnel of Immuron Limited during the financial year ended June 30, 2018: Dr. Jerry Kenellos, Interim Chief Executive Officer (CEO), (appointed August 3, 2017) and Chief Operating & Scientific Officer (COSO) Mr. Thomas Liquard, Chief Executive Officer (CEO), (resigned August 3, 2017) The aggregate compensation made to Directors and Other Key Management Personnel of the Company is set out below: 30 June 2018 AUD$ 30 June 2017 AUD$ 30 June 2016 AUD$ Key Management Personnel Compensation Short-term employee benefits 570,256 681,666 652,514 Post-employment benefits 32,087 25,947 26,004 Share-based payments 59,975 353,670 1,606,275 Total Key Management Personnel Compensation 662,318 1,061,283 2,284,793

Loss per Share

Loss per Share	12 Months Ended
	Jun. 30, 2018
Loss Per Share
Loss per Share	Note 6. Loss per Share 30 June 2018 30 June 2017 30 June 2016 AUD$ AUD$ AUD$ Basic/Diluted loss per share (in cents) 2.300 6.400 9.248 a) Net loss used in the calculation of basic and diluted loss per share 3,010,929 6,804,154 7,068,767 b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share 133,660,556 105,866,110 76,435,993 * * This amount includes 182,169 of weighted average shares for ordinary shares in relation to the A$4,511,378 received in capital raising that was not issued as of 30 June 2016. The Company is currently in a loss making position and thus the impact of potential issuance of shares is concluded as anti-dilutive which includes the Company’s options and warrants and convertible notes payable. Treasury shares are excluded from the calculation of weighted average number of ordinary shares.

Cash

Cash	12 Months Ended
	Jun. 30, 2018
Cash and cash equivalents [abstract]
Cash	Note 7. Cash 30 June 2018 30 June 2017 Cash at Bank and in hand: Cash at bank and in hand 4,727,430 3,994,924 Total Cash 4,727,430 3,994,924 The interest rate on cash at bank at 30 June 2018 was 0.4% (2017: 1%)

Trade and Other Receivables

Trade and Other Receivables	12 Months Ended
	Jun. 30, 2018
Trade and other receivables [abstract]
Trade and Other Receivables	Note 8. Trade and Other Receivables 30 June 2018 AUD$ 30 June 2017 AUD$ Current Trade receivables* 492,276 270,125 Accrued income** 1,191,029 1,498,112 Total Trade and Other Receivables 1,683,305 1,768,237 * All trade receivables are non-interest bearing. ** Primarily comprises of receivables from the Australian Tax Office in relation to R&D tax concession for the year.

Inventories

Inventories	12 Months Ended
	Jun. 30, 2018
Inventories Abstract
Inventories	Note 9. Inventories 30 June 2018 30 June 2017 Current Inventory Raw materials 198,585 1,793,882 Work in Progress 33,625 48,425 Finished goods 265,692 357,478 Prepaid inventory and supplies — 136,342 Total Inventory 497,902 2,336,127 At 30 June 2017, management classified the inventory as a current asset as it was expected and assessed that it would be sellable in the next 12 months based on the combination of sales to an alternative market for the Colostrum powder, as well as forecasted manufacturing quantities. During the current financial period, management has performed an assessment on its raw materials and utilization within 12 months from reporting date and have determined AUD$198,585 of raw materials relating to Colostrum will be consumed within 12 months and the remaining balance of AUD$2,171,867 will be consumed after 12 months from reporting date. During the year ended June 30, 2018, management determined that a portion of its inventory should be reclassified on a prospective basis as a noncurrent asset as a result of a strategic decision made by management in the intended use of its inventory. The Company decided to terminate all plans to sell the colostrum powder to secondary markets as a result of the continued scientific evidence supporting an extended shelf life. The extended shelf life provides the Company with the assurance that colostrum will be consumed through the production of its current Travelan and Protectyn products throughout future reporting periods. 30 June 2018 30 June 2017 Non-Current Inventory Raw materials 2,171,867 — Total Non-Current Inventory 2,171,867 — During the year ended June 30, 2018, management determined that a portion of its inventory should be reclassified on a prospective basis as a noncurrent asset as a result of a strategic decision made by management in the intended use of its inventory. The Company decided to terminate all plans to sell the colostrum powder to secondary markets as a result of the continued scientific evidence supporting an extended shelf life. The extended shelf life provides the Company with the assurance that all colostrum will be consumed through the production of its current Travelan and Protectyn products throughout future reporting periods.

Controlled Entities

Controlled Entities	12 Months Ended
	Jun. 30, 2018
Controlled Entities
Controlled Entities	Note 10. Controlled Entities The Company’s subsidiaries at 30 June 2018 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held equals the voting rights held by the Company. The country of incorporation or registration is also their principal place of business. Country of Percentage of Ownership Incorporation 30 Jun 2018 30 Jun 2017 Parent Entity: Immuron Limited Australia — — Subsidiaries of Immuron Limited: Immuron Inc. USA 100 % 100 % Anadis EPS Pty Ltd Australia 100 % 100 % IMC Canada Ltd. Canada 100 % 0 %

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Jun. 30, 2018
Trade and other payables [abstract]
Trade and Other Payables	Note 11. Trade and Other Payables 30 June 2018 30 June 2017 AUD$ AUD$ Current Trade payables 216,938 699,530 Accrued expenses 435,280 568,988 Other payables 37,108 21,871 Total 689,326 1,290,389

Other Liabilities

Other Liabilities	12 Months Ended
	Jun. 30, 2018
Other Liabilities
Other Liabilities	Note 12. Other Liabilities 30 June 2018 30 June 2017 AUD$ AUD$ Other Liabilities Convertible Notes* — 226,000 Deferred Revenue** — 19,139 Borrowings*** — 139,864 Total — 385,003 (*) Convertible Notes: On 17 February 2016, the Company secured A$1,700,000 in funding with a New York-based Investment Fund. The facility was used to fund the immediate start of the clinical phase for IMM-529 in Clostridium difficile The investment was structured in 3 tranches with a mix of equity financing and convertible securities according to the following: Tranche #1 - A$100,000 private placement of securities plus a A$600,000 repayable Convertible Notes with A$78,000 finance charge; Tranche #2 - 45 days after issuance of the tranche 1, the Company has the right to call a second Tranche as per Tranche 1 terms. Tranche #3 - by mutual consent, A$339,000 Face Value repayable Convertible Notes issuable on same terms as Tranche 1 and 2. The Convertible Notes were repayable monthly over an 18 month period with each repayment to be settled at Immuron’s discretion by: a) the issuance of new shares at a 10% discount to a 5 Day Volume Weighted Average Price (VWAP) over the 20 trading days immediately prior to a repayment due date; or b) cash repayment plus a 2.5% premium to the repayment amount. Immuron drew down Tranche 1 and Tranche 2 of the Convertible Note during fiscal year 2016. Immuron repaid A$902,117 in cash during the 2017 financial year and repaid A$77,217 in cash and A$150,666 in shares prior to 30 June 2016, as disclosed under Note 15. The balance of the outstanding convertible note as at 30 June 2017 was repaid during July 2017 and August 2017 with the liability being fully extinguished by 10 September 2017. (**) Deferred Revenue: This amount represents amounts billed by the Company for undelivered goods. (***) Borrowings: The Company has financed A$162,457 for its insurance policies during the year ended June 30, 2017. Principal and interest (A$8,561) is to be repaid monthly by Immuron over a 11-month term. During the financial year 2018, the outstanding borrowings were repaid by the Company.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2018
Commitments And Contingencies
Commitments and Contingencies	Note 13. Commitments and Contingencies 30 June 2018 AUD$ Lease commitments not recognized in the financial statements: - not later than 12 months 19,470 - between 1 and 5 years — Total 19,470 1 The property lease is a non-cancellable lease with a 3 year term, with rent payable monthly in advance. The minimum lease payments shall be increased by CPI per annum. An option exists to renew the lease at the end of the 3 year term for an additional term of 3 years. The current 3 year lease period expires in December 2018. The Group has recognised A$38,917, A$46,082 and A$25,501, of rental expenses in its Statement of Profit or Loss and Other Comprehensive Income for the years 2018, 2017 and 2016, respectively, as Corporate Administration Expense.

Contributed Equity

Contributed Equity	12 Months Ended
	Jun. 30, 2018
Contributed Equity
Contributed Equity	Note 14. Contributed Equity 30 June 2018 30 June 2017 30 June 2016 No. AUD$ No. AUD$ No. AUD$ Fully Paid Ordinary Shares (No par value) Balance at Beginning of year 130,041,417 53,632,995 80,099,646 45,633,354 74,964,232 40,335,347 Capital consolidation (40:1) — — — — Shares issued during the year 14,736,789 5,472,200 49,941,771 9,965,323 5,135,414 1,721,789 Shares to be issued(*) — — — 4,511,378 Transactions costs (733,152 ) — (2,037,557 ) — (135,160 ) Cancellation of shares (2,000,000 ) — — — — — Treasury shares — — — — — (800,000 ) Movement to Retained Earnings — — — 71,875 — — Total Contributed Equity 142,778,206 58,372,043 130,041,417 53,632,995 80,099,646 45,633,354 (*) As at 30 June 2016, the Company was committed to issue 18,045,512 ordinary shares in relation to the A$4,511,378 received in capital raising. During the Full Year ended 30 June 2018, the Company issued the following securities: Date Details No. Issue Price AUD$ Total Value AUD$ 28-Jul-17 Issue of Equity for the repayment of Sea Otter 16th payment of Convertible Note 399,045 0.19 75333 13-Nov-17 Issue of Shares to Grandlodge 875,000 0.16 140,000 15-Mar-18 Private Placement to US Investment Fund 13,162,744 0.39 5,161,585 15-Mar-18 Exercise of NASDAQ Warrants (IMRNW) 300,000 0.32 95,282 Total 2018 Movement 14,736,789 5,472,200 During the Full Year ended 30 June 2017, the Company issued the following securities: Date Details No. Issue Price Total Value 7 Jul 2016 Right issue* 18,045,512 — — 7 Jul 2016 Right issue 3,275,466 0.25 818,867 29 Sep 2016 Right issue to oversubscribes and private placement 3,968,916 0.25 992,229 2 Dec 2016 Shares under ESOP – for 6 months service (vesting monthly) 251,877 0.245 61,710 9 Jun 2017 Shares issued on NASDAQ (equivalent to 610,000 ADSs)** 24,400,000 0.332 8,092,517 Total 2017 Movement 49,941,771 9,965,323 (*) As at 30 June 2016, the Company was committed to issue 18,045,512 of ordinary shares in relation to the A$4,511,378 received in capital raising. These shares were subsequently issued to respective holders on 7 July 2016. 2,418,129 of these new fully paid ordinary shares were issued to Grandlodge on the same terms and conditions as all other subscribers. (**) Grandlodge participated in our NASDAQ IPO and acquired 32,707 ADRs and 32,707 Warrants. During the Full Year ended 30 June 2016, the Company issued the following securities: Date Details No. Issue Price AUD$ Total Value AUD$ 18 Sep 2015 Exercise of IMCAI Unlisted Options 218,750 0.376 82,250 30 Sep 2015 Exercise of IMCAI Unlisted Options 93,750 0.376 35,250 19 Oct 2015 Exercise of IMCAI Unlisted Options by Grandlodge 556,000 0.376 209,056 13 Nov 2015 Exercise of IMCAI Unlisted Options 41,666 0.376 15,667 27 Nov 2015 Issue of Shares in lieu of cash payment for services as per Resolution 4 of the Annual General Meeting (AGM) held on 25 Nov 2015 546,875 0.160 87,500 24 Feb 2016 Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016 294,118 0.340 100,000 24 Feb 2016 Issue of fully paid escrow shares as security for any repayment default of the Convertible Loan in accordance with executed funding agreement with a New York based Investment fund provider and announced to the ASX on 17 Feb 2016 2,000,000 0.400 800,000 13 Apr 2016 Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016 326,797 0.306 100,000 18 Apr 2016 First repayment of Convertible Notes Security in accordance with executed funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016 241,764 0.312 75,333 16 May 2016 Exercise of IMCAI Unlisted Options 150,000 0.276 41,400 16 May 2016 Second repayment of Convertible Notes Security in accordance with executed funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016 265,694 0.284 75,333 31 May 2016 Issue of Shares in lieu of cash payment for services received 400,000 0.250 100,000 30 Jun 2016 Shares to be Issued from Capital Raising as at 30 June 2016 — — 4,511,378 Total 2016 Movement 5,135,414 6,233,167 The value of all share based payments of stock is per the terms of an underlying agreement or based on the fair value of the stock on the date of the transaction. Ordinary shares participate in dividends and the proceeds on winding up of the Company in proportion to the number of shares held. At shareholder meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands. The ordinary shares have no par value.

Reserves

Reserves	12 Months Ended
	Jun. 30, 2018
Reserves Abstract
Reserves	Note 15. Reserves Nature and Purpose of the Reserve The reserve recognizes option reserves which are the expense recognized in respect of share-based payments, and foreign currency translation reserve arising from translation of foreign subsidiary. 30 June 2018 30 June 2017 30 June 2016 No. AUD$ No. AUD$ No. AUD$ Options over Fully Paid Ordinary Shares Balance at Beginning of year 63,690,523 2,434,135 9,937,629 2,132,301 7,188,676 560,646 Capital consolidation (40:1) — — — — Options issued during the year 8,424,157 156,392 56,002,894 136,784 7,425,532 285,600 Granted options to be issued(*) — — — — Options exercised during the year (300,000 ) — — — (1,060,166 ) (71,875 ) Expense of vested options — 59,975 — 333,950 — 1,606,275 Lapse of unexercised options (465,500 ) (463 ) (2,250,000 ) (168,900 ) (3,616,413 ) (248,345 ) Closing Balance 71,349,180 2,650,039 63,690,523 2,434,135 9,937,629 2,132,301 Foreign currency translation reserve Opening balance 36,282 (3,735 ) (12,581 ) Movement during the year — (79,599 ) — 40,017 — 8,846 Closing balance — (43,317 ) 36,282 (3,735 ) Total Reserves 71,349,180 2,606,722 63,690,523 2,470,417 9,937,629 2,128,566 (*) On 9 December 2016, the Company issued 1 million options exercisable at A$0.50 per option expiring on April 1, 2017 to an employee under the Company’s ESOP following the successful completion of the related milestone pertaining to a minimum recruitment of 100 patients into the Company’s NASH Phase 2 clinical trial During the Full Year ended 30 June 2018, the Company issued the following options: Date Details No. AUD$ AUD$ 15-Mar-18 Issue of options- Free-attaching 3 options for every 5 new shares as a part of the capital raise 7,897,647 — — 15-Mar-18 Issue of options - Broker shares as part of placement fee 526,510 0.3 156,392 Total 2018 Movement 8,424,157 156,392 During the Full Year ended 30 June 2017, the Company issued the following options: Date Details No. AUD$ AUD$ 7 Jul 2016 Right issue** 18,045,512 — — 7 Jul 2016 Right issue 3,275,466 — — 29 Sep 2016 Right issue to oversubscribes and private placement 3,968,916 — — 9 Dec 2016 Unlisted options in lieu of services 200,000 0.143 28,620 9 Jun 2017 Options issued to cover equivalent of 610,000 warrants on issue with NASDAQ 24,400,000 0.00033 8,101 9 Jun 2017 Options issued to cover equivalent of 35,075 warrants on issue with NASDAQ 1,403,000 0.00033 463 13 Jun 2017 Options issued to cover equivalent of 91,500 warrants on issue with NASDAQ 3,660,000 0.00033 1,215 22 Jun 2017 Unlisted options in lieu of services 1,050,000 0.094 98,385 Total 2017 Movement 56,002,894 136,784 (**) As of 30 June 2016, the Company was committed to issue 18,045,512 options in relation to the A$4,511,378 received in capital raising. These options were subsequently issued to respective holders on 7 July 2016. 2,418,129 of these options were issued to Grandlodge on the same terms and conditions as all other subscribers. On 22 June 2017, the Company issued Professor Ravi Savarirayan, a Non-Executive Director of Immuron Limited, 1,000,000 unlisted options exercisable at A$0.50 on or before 27 Nov 2019. During the Annual General Meeting in 2018, the shareholders approved the issuance of the options to Ravi Savarirayan. During the Full Year ended 30 June 2016, the Company issued the following options: Date No. Issue Price AUD$ Total Value AUD$ 27 Nov 2015 Issue of Unlisted Options in lieu of cash payment for additional services as per Resolution 5A - 5D of the AGM held on 25 Nov 2015 6,000,000 — 1,606,275 18 Feb 2016 Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016 1,000,000 0.186 185,600 31 May 2016 Issue of Unlisted Options in lieu of cash payment for services received 425,532 0.235 100,000 Total 2016 Movement 7,425,532 1,891,875

Segments Reporting

Segments Reporting	12 Months Ended
	Jun. 30, 2018
Segments Reporting
Segments Reporting	Note 16. Segments Reporting Primary Reporting Format - Business Segments The entity has identified its operating segments based on the internal reports that are reviewed and used by the chief operating decision makers in assessing performance and determining the allocation of resources. The executive management team considers the business from both a product and a geographic perspective and has identified three reportable segments. Segments Research and Development (R&D) – Income and expenses directly attributable to the Company’s research and development projects performed in Australia and Israel. HyperImmune Products – Income and expenses directly attributable to Travelan activities which occur in Australia, New Zealand, Canada and the United States. In 2018, the Company earned 62%, 1% and 37% of its revenues from customers located in Australia, Canada and United States, respectively In 2017, the Company earned 64%, 10% and 26% of its revenues from customers located in Australia, Canada and United States, respectively. In 2016, the Company earned 78% and 4% and 18% of its revenues from customers located in Australia, Canada and United States, respectively. Unallocated Corporate – Other items of income and expenses not directly attributable to R&D or HyperImmune Products segment are disclosed as corporate costs. Corporate activities primarily occur within Australia. This segment includes interest expenses from financing activities and depreciation. Research & Development HyperImmune Products Unallocated Corporate Total 30 June 2018 AUD$ AUD$ AUD$ AUD$ Segment Revenue & Other income Revenue from external customers — 1,842,909 — 1,842,909 R&D tax concession refund 1,849,123 — 1,238 1,850,361 Other income — 40 — 40 Total Segment Revenues & Other income 1,849,123 1,842,949 1,238 3,693,310 Segment Expenses Depreciation — — (5,047 ) (5,047 ) Finance costs — — (18,857 ) (18,857 ) Share-based payments — — (59,975 ) (59,975 ) Other operating expenses (2,257,224 ) (832,661 ) (3,530,475 ) (6,620,360 ) Total Segment Expenses (2,257,224 ) (832,661 ) (3,614,354 ) (6,704,239 ) Income Tax Expenses — — — — (Loss)/Profit for the Period (408,101 ) 1,010,288 (3,613,116 ) (3,010,929 ) Assets Segment assets 1,191,029 3,162,045 4,889,614 9,242,688 Total Assets 1,191,029 3,162,045 4,889,614 9,242,688 Liabilities Segment liabilities (174,434 ) (26,009 ) (602,895 ) (803,338 ) Total Liabilities (174,434 ) (26,009 ) (602,895 ) (803,338 ) Research & Development HyperImmune Products Unallocated Corporate Total 30 June 2017 AUD$ AUD$ AUD$ AUD$ Segment Revenue & Other income Revenue from external customers — 1,396,197 — 1,396,197 R&D tax concession refund 1,575,315 — — 1,575,315 Interest income — — 8,386 8,386 Other income 25,000 5,672 — 30,672 Total Segment Revenues & Other income 1,600,315 1,401,869 8,386 3,010,570 Segment Expenses Depreciation — — (4,922 ) (4,922 ) Finance costs — — (24,483 ) (24,483 ) Share-based payments (188,481 ) — (334,184 ) (522,665 ) Other operating expenses (4,805,874 ) (1,017,169 ) (3,439,611 ) (9,262,654 ) Total Segment Expenses (4,994,355 ) (1,017,169 ) (3,803,200 ) (9,814,724 ) Income Tax Expenses — — — — (Loss)/Profit for the Period (3,394,040 ) 384,700 (3,794,814 ) (6,804,154 ) Assets Segment assets 1,498,112 2,585,755 4,202,624 8,286,491 Total Assets 1,498,112 2,585,755 4,202,624 8,286,491 Liabilities Segment liabilities (514,326 ) (330,218 ) (867,021 ) (1,711,565 ) Total Liabilities (514,326 ) (330,218 ) (867,021 ) (1,711,565 ) Research & Development HyperImmune Products Unallocated Corporate Total 30 June 2016 AUD$ AUD$ AUD$ AUD$ Segment Revenue & Other income Revenue from external customers — 1,001,077 — 1,001,077 R&D tax concession refund 1,512,840 — — 1,512,840 Interest income — — 12,165 12,165 Other income — 10,200 3,810 14,010 Total Segment Revenues & Other income 1,512,840 1,011,277 15,975 2,540,092 Segment Expenses Depreciation — — (3,892 ) (3,892 ) Finance costs — — (156,000 ) (156,000 ) Share-based payments — — (2,079,375 ) (2,079,375 ) Other operating expenses (3,623,961 ) (570,183 ) (3,175,448 ) (7,369,592 ) Total Segment Expenses (3,623,961 ) (570,183 ) (5,414,715 ) (9,608,859 ) Income Tax Expenses — — — — (Loss)/Profit for the Period (2,111,121 ) 441,094 (5,398,740 ) (7,068,767 ) Assets Segment assets 1,512,840 2,318,860 4,995,784 8,827,484 Total Assets 1,512,840 2,318,860 4,995,784 8,827,484 Liabilities Segment liabilities (769,434 ) (538,806 ) (2,578,681 ) (3,886,921 ) Total Liabilities (769,434 ) (538,806 ) (2,578,681 ) (3,886,921 ) Information on major customers: During the years ended 30 June 2018, 2017 and 2016, the Company had the following major customers (and their respective contribution to the Group’s total revenue): 2018 2017 2016 Customer A 31 % 13 % 16 % Customer B 25 % 34 % 43 % Customer C 12 % 15 % 22 % Customer D 10 % 15 % * Customer E * 10 % * * Less than 10% of revenue for the respective year. No other single customers contributed 10% or more to the Group’s revenue for all periods.

Cash Flow Information

Cash Flow Information	12 Months Ended
	Jun. 30, 2018
Cash Flow Information
Cash Flow Information	Note 17. Cash Flow Information (a) Reconciliation of cash flow from operations with loss after income tax 30 June 2018 AUD$ 30 June 2017 AUD$ 30 June 2016 AUD$ Net Loss for the Year (3,010,929 ) (6,804,154 ) (7,068,767 ) Non-Cash Add depreciation expense 5,047 4,922 3,892 Add change in fair value and interest accrued on borrowings — 8,561 178,401 Add back equity issued for non-cash consideration* — — 187,500 Add back share based payments expense 242,950 522,665 1,891,875 Changes in Working Capital Add decreases / (increases) in current trade and other receivables 84,932 7,396 (84,004 ) Add decreases / (increases) in other current assets 26,561 69,034 (30,015 ) Add (increases) in inventory (333,642 ) (280,060 ) (909,800 ) Add (decreases) / increases in current trade and other payables and deferred revenue (620,202 ) (559,452 ) 672,582 Add (decrease) increase in provisions 77,839 — — (3,527,444 ) (7,031,088 ) (5,158,336 ) * The cost of A$187,500 relates to issue of shares worth A$87,500 in lieu of cash payments for services to Advanced Clinical Systems International as per resolution 4 of the AGM held on 25 November 2015. Additionally, shares worth A$100,000 were issued to The CFO Solution in lieu of services on 31 May 2016. (b) Non-cash financing and investing activities See Note 8 for details on the uncleared funds of A$2,612,139 from capital raising as at 30 June 2016. An amount of A$114,861 of capital raising costs were recognised as expenses but remained unpaid during the period as at 30 June 2016. The Company has financed A$162,457 for its insurance policies during the year ended June 30, 2017, which was recorded to Borrowings and Other Assets as of June 30, 2017. During the financial year 2018, the balance of the outstanding convertible note as at 30 June 2017 was repaid during July 2017 and August 2017 with the liability being fully extinguished by 10 September 2017. See Note 19 for details regarding issues of options to employees and for details surrounding the issue of shares to suppliers.

Share-based Payments

Share-based Payments	12 Months Ended
	Jun. 30, 2018
Share-based Payments
Share-based Payments	Note 18. Share-based Payments Executives and consultants may be provided with longer-term incentives through the Company’s ESOP, to allow the executives and consultants to participate in, and benefit from, the growth of the Company as a result of their efforts and to assist in motivating and retaining these key employees over the long term. (a) Options Issued under the ESOP The following table illustrates the number and weighted average exercise price of and movement in share options issued under the scheme during the year: 30 June 2018 30 June 2017 30 June 2016 Number of Weighted Number of Weighted Number of Weighted Outstanding at the beginning of the year 1,312,500 0.550 1,062,500 1.560 1,856,150 0.440 Capital consolidation (40:1) — — — — Options granted during the year — — 1,250,000 0.500 — — Granted options to be issued* — — — — Options exercised — — (150,000 ) 0.276 Lapse of unexercised options — — (1,000,000 ) 0.500 (643,650 ) 0.276 Options Outstanding at End of the Year 1,312,500 0.550 1,312,500 0.550 1,062,500 0.562 Options Exercisable at the End of the Year 1,312,500 0.550 1,312,500 0.550 62,500 1.556 The options outstanding at 30 June 2018 have a weighted average remaining contractual life of 1.39 years (2017: 1.39 years) and exercise prices ranging from A$0.50 to A$1.56 (2017: from A$0.50 to A$1.56). (b) Options Issued to Directors The following table illustrates the number and weighted average exercise price of and movement in share options issued to directors during the year: 30 June 2018 30 June 2017 30 June 2016 Number of Weighted Number of Weighted Number of Weighted Outstanding at the beginning of the year 6,000,000 0.500 7,000,000 0.456 1,000,000 0.456 Capital consolidation (40:1) — — — — Options granted during the year — — 6,000,000 0.500 Lapse of unexercised options — — (1,000,000 ) 0.460 — — Options Outstanding at End of the Year 6,000,000 0.500 6,000,000 0.500 7,000,000 0.494 Options Exercisable at the End of the Year 6,000,000 0.500 5,000,000 0.500 1,000,000 0.456 The options outstanding at 30 June 2018 have a weighted average remaining contractual life of 2.41 years (2017: 2.41 years) and exercise price of A$0.50 (2017: A$0.50). On 22 June 2017, the Company issued Professor Ravi Savarirayan, a Non-Executive Director of Immuron Limited, 1,000,000 unlisted options exercisable at A$0.50 on or before 27 Nov 2019. (c) Other options/warrants issued 30 June 2018 30 June 2017 30 June 2016 Number of Weighted Number of Weighted Number of Weighted Outstanding at the beginning of the year 56,378,023 0.440 1,875,129 0.561 4,332,526 0.400 Capital consolidation (40:1) — — — — Options granted during the year 8,424,157 0.470 54,752,894 0.430 1,425,532 0.549 Options exercised (300,000 ) — — (910,166 ) 0.376 Lapse of unexercised options (465,500 ) 1.550 (250,000 ) 0.460 (2,972,763 ) 0.376 Options Outstanding at End of the Year 64,036,680 0.470 56,378,023 0.440 1,875,129 0.561 Options Exercisable at the End of the Year 64,036,680 0.470 56,378,023 0.440 1,875,129 0.561 The options outstanding at 30 June 2018 have a weighted average remaining contractual life of 4.589 years (2017: 3.57 years) and exercise prices ranging from A$0.30 to A$1.94 (2017: from A$0.30 to A$1.944). (d) Vesting Terms of Options The following summarizes information about options held by employees, Directors and third parties as at 30 June 2018: Issue Date Number of Options Vesting Conditions Expiry Date Exercise Price AUD$ 29-Jun-12 14,493 Nil 30-Nov-21 AUD$ 1.944 29-Jun-12 29,668 Nil 17-Jan-22 AUD$ 1.876 3-Mar-14 15,380 Nil 28-Feb-19 AUD$ 1.892 29-May-14 140,056 Nil 28-May-19 AUD$ 0.300 27-Nov-15 6,000,000 See below 27-Nov-19 AUD$ 0.500 18-Feb-16 1,000,000 Nil 24-Feb-19 AUD$ 0.570 31-May-16 425,532 Nil 27-Nov-19 AUD$ 0.500 7-Jul-16 25,289,894 Nil 30-Nov-19 AUD$ 0.550 9-Dec-16 200,000 Nil 27-Nov-19 AUD$ 0.500 9-Jun-17 24,400,000 Nil 13-Jun-22 AUD$ 0.326 13-Jun-17 3,660,000 Nil 13-Jun-22 AUD$ 0.326 22-Jun-17 1,050,000 Nil 1-Oct-18 AUD$ 0.500 22-Jun-17 1,000,000 Nil 27-Nov-19 AUD$ 0.500 15-Mar-18 7,897,647 Nil 15-Mar-23 AUD$ 0.468 15-Mar-18 526,510 Nil 15-Mar-23 AUD$ 0.585 November 2015 Options The options with an issue date of 27 November 2015, entitle the holder to purchase one ordinary share in Immuron Limited at an exercise price of A$0.500. Options vest based on month of continuous services completed as per the following: - 5,000,000 Options which vested on 6 August 2016 – subject to completion of 12 months’ continuous services as a Director of the Company - 1,000,000 Options which vested on 6 August 2017 – subject to completion of 24 months’ continuous services as a Director of the Company (e) Deemed Valuation of Options The fair value of options granted by the company as stock-based compensation is estimated as at the grant date using Black-Scholes model taking into account the terms and conditions upon which the options were granted. November 2015 Options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date As per above Dividend yield — Expected volatility 100 % Risk-free interest rate 2.11 % Expected life of option (years) 4 years Option exercise price AUD$ 0.5000 Weighted average share price at grant date AUD$ 0.465 Value per option AUD$ 0.3186 February 2016 Options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date N/A Dividend yield — Expected volatility 97 % Risk-free interest rate 1.73 % Expected life of option (years) 3 years Option exercise price AUD$ 0.5700 Weighted average share price at grant date AUD$ 0.36 Value per option AUD$ 0.1856 May 2016 Options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date N/A Dividend yield — Expected volatility 84 % Risk-free interest rate 2.11 % Expected life of option (years) 4 years Option exercise price AUD$ 0.5000 Weighted average share price at grant date AUD$ 0.41 Value per option AUD$ 0.235 December 2016 Options Pursuant to an agreement entered between the Company and a consultant on April 1, 2015, the Company granted 1,000,000 options, which were issued and vested on 9 December 2016, and each option entitles the holder to purchase one ordinary share of the Company at an exercise price of A$0.500. These options were issued and vested following the successful completion of related milestone pertaining to a minimum recruitment of 100 patients into the Company’s NASH Phase 2 clinical trial. The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date N/A Dividend yield — Expected volatility 100 % Risk-free interest rate 1.69 % Expected life of option (years) 3.17 years Option exercise price AUD$ 0.5000 Weighted average share price at grant date AUD$ 0.285 Value per option AUD$ 0.1431 June 2017 Options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date N/A Dividend yield — Expected volatility 100 % Risk-free interest rate 1.69 % Expected life of option (years) 1.33 years Option exercise price AUD$ 0.5000 Weighted average share price at grant date AUD$ 0.315 Value per option AUD$ 0.0937 The expected life of the options is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2018
Related party transactions [abstract]
Related Party Transactions	Note 19. Related Party Transactions The transactions with related parties are as follows: 30 June 2018 30 June 2017 30 June 2016 Short-term Loan from Grandlodge Capital Pty Ltd Grandlodge Capital Pty Ltd (Grandlodge) is an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou. Mr David Plush is also an owner of Grandlodge, and its associated entities. On 1 December 2015, 6 June 2016 and 9 May 2017, Immuron executed a short-term funding agreement with Grandlodge for a principle amount of $1,000,000 (interest rate 13%), $750,000 (interest rate 15%) and $500,000 (interest rate 15%) respectively. The short-term funding is a cash advance against the anticipated refund Immuron will receive from the Australian Taxation Office under the Research and Development Income Tax Concession Incentive for the Company’s eligible R&D expenditure incurred for financial year of 2015, 2016 and 2017. Loan from December 2016, June 2016 and May 2017, plus applicable fees and interest, was repaid to Grandlodge on 10 February 2016, 2 December 2016 and 23 June 2017, respectively. Interest expense was approximately $57,000 and $31,000 for the years ended 30 June 2017 and 2016, respectively. In addition, the Company incurred approximately $35,000 of loan fees for the year ended 30 June 2016. Total paid by the Company to Grandlodge Pty Ltd during the year: — 1,329,007 1,043,863 At year end the Company owed Grandlodge Pty Ltd: — — 772,397 30 June 2018 30 June 2017 30 June 2016 Service rendered by Grandlodge Pty Ltd to Immuron Ltd: Grandlodge, and its associated entities, are marketing, warehousing and distribution logistics companies. Commencing on 1 June 2013, Grandlodge to provide warehousing, distribution and invoicing services for Immuron’s products for $70,000 per annum. These fees will be payable in new fully paid ordinary shares in Immuron Limited at a set price of $0.16 per share representing Immuron Limited’s share price at the commencement of the agreement. The shares to be issued to Grandlodge, or its associated entities, as compensation in lieu of cash payment for the services rendered under this agreement have been subject to the approval of Immuron shareholders at Company shareholder meetings held over the past 18 months. Grandlodge will also be reimbursed in cash for all reasonable costs and expenses incurred in accordance with their scope of works under the agreement, unless both parties agree to an alternative method of payment. The agreement is cancellable by either party upon providing the other party with 30 days written notice of the termination of the agreement. Service fees paid to Grandlodge Pty Ltd during the year through the issue of equity: 140,000 — 87,500 Total paid by the Company to Grandlodge Pty Ltd during the year: — — 87,500 At year end the Company owed Grandlodge Pty Ltd: 35,000 105,000 35,000 30 June 2018 30 June 2017 30 June 2016 Premises rental services received from Wattle Laboratories Pty Ltd to Immuron Limited: Wattle Laboratories Pty Ltd (Wattle) is an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou. Commencing on 1 January 2016, Immuron executed a Lease Agreement with Wattle whereby Immuron will lease part of their Blackburn office facilities for Immuron’s operations at rental rate of $38,940 per annum, payable in monthly instalments. The rental agreement is subject to annual rental increases, and effective 1 January 2017, the annual rent was increased to $39,525. The lease is for a 3 year term with an additional 3 year option period. The lease is cancellable by either party upon 6 months written notice of termination of the agreement. Rental fees paid to Wattle Laboratories Pty Ltd during the year through the issue of equity: Total paid by the Company to Wattle Laboratories Pty Ltd during the year: 33,020 35,792 19,470 At year end the Company owed Wattle Laboratories Pty Ltd: — — 21,417 30 June 2018 30 June 2017 Service rendered by Great Accommodation Pty Ltd to Immuron Ltd: During the current financial year, the Company entered into a short-term loan arrangement with Great Accommodation Pty Ltd to fund on going R&D expenditure, for an amount of AUD $500,000 at an interest rate of 15% per annum and a AUD $15,000 establishment fee. The loan was repaid on 12 February 2018. Total paid by the Company to Great Accommodation Pty Ltd during the year: 520,342 — At year end the Company owed Great Accommodation Pty Ltd: — —

Financial Risk Management Objec

Financial Risk Management Objectives and Policies	12 Months Ended
	Jun. 30, 2018
Financial Risk Management Objectives And Policies
Financial Risk Management Objectives and Policies	Note 20. Financial Risk Management Objectives and Policies (a) Financial Instruments The Company’s financial instruments consist of cash, trade and other receivables, trade and other payables, borrowings and Convertible Notes: 30 June 2018 AUD$ 30 June 2017 AUD$ Cash 4,727,430 3,994,924 Trade receivables 492,276 1,768,237 Trade and other payables (689,326 ) (1,290,389 ) Borrowings (See Notes 13 and 20) — (139,864 ) Convertible notes — (226,000 ) The fair values of cash, trade and other receivables, trade and other payables, borrowings and convertible notes approximate their carrying amounts largely due to being liquid assets and payables will be settled within 12 months. (b) Risk Management Policy The Board is responsible for overseeing the establishment and implementation of the risk management system, and reviews and assesses the effectiveness of the Company’s implementation of that system on a regular basis. The Board and Senior Management identify the general areas of risk and their impact on the activities of the Company, with Management performing a regular review of: the major risks that occur within the business; the degree of risk involved; the current approach to managing the risk; and if appropriate, determine: ○ any inadequacies of the current approach; and ○ possible new approaches that more efficiently and effectively address the risk. Management report risks identified to the Board through the monthly Operations Report. The Company seeks to ensure that its exposure to undue risk which is likely to impact its financial performance, continued growth and survival is minimised in a cost effective manner. (c) Significant Accounting Policies Details of significant accounting policies and methods adopted, including the criteria for recognition, the basis for measurement and the basis on which income and expenses are recognised, in respect of each class of financial asset, financial liability and equity instrument are disclosed in Note 1 to the financial statements. The carrying amounts of cash, trade and other receivables, trade and other payables and financial liabilities represents their fair values determined in accordance with the accounting policies disclosed in Note 1. Interest income on cash is disclosed in Note 2. (d) Capital Risk Management The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern and to maintain an optimal capital structure so as to maximise shareholder value. In order to maintain or achieve an optimal capital structure, the Company may issue new shares or reduce its capital, subject to the provisions of the Company’s constitution. The capital structure of the Company consists of equity attributed to equity holders of the Company, comprising contributed equity, reserves and accumulated losses disclosed in Notes 15 and 16. By monitoring undiscounted cash flow forecasts and actual cash flows provided to the Board by the Company’s Management the Board monitors the need to raise additional equity from the equity markets. Financial Risk Management The main risks the Company is exposed to through its operations are interest rate risk, foreign exchange risk, credit risk and liquidity risk. Interest Rate Risk The Company is exposed to interest rate risks via the cash and borrowings that it holds. Interest rate risk is the risk that a financial instruments value will fluctuate as a result of changes in market interest rates. The objective of managing interest rate risk is to minimise the Company’s exposure to fluctuations in interest rate that might impact its interest revenue and cash flow. Interest rate risk is considered when placing funds on term deposits. The Company considers the reduced interest rate received by retaining cash in the Company’s operating account compared to placing funds into a term deposit. This consideration also takes into account the costs associated with breaking a term deposit should early access to cash be required. There has been no change to the Company’s exposure to interest rate risk or the manner in which it manages and measures its risk in the year ended 30 June 2018 Foreign Currency Risk The Company is exposed to foreign currency risk via the trade and other receivables and trade and other payables that it holds. Foreign currency risk is the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company aims to take a conservative position in relation to foreign currency risk hedging when budgeting for overseas expenditure however, the Company does not have a policy to hedge overseas payments or receivables as they are highly variable in amount and timing, due to the reliance on activities carried out by overseas entities and their billing cycle. The following financial assets and liabilities are subject to foreign currency risk: 30 June 2018 AUD$ 30 June 2017 AUD$ Cash (AUD/USD) 4,222,310 2,770,682 Trade and other receivable (AUD/USD) 161,138 126,207 Trade and other payables (AUD/USD) 57,667 502,651 Trade and other payables (AUD/CHF) — Trade and other payables (AUD/NZD) — Trade and other payables (AUD/ISL) 4,320 20,489 Foreign Currency purchase: On 25 August 2016 on behalf of Immuron, Grandlodge purchased US$1,500,000 at the cost of A$1,968,762. On the same day Immuron paid Grandlodge A$1,968,762 to settle this transaction. On 12 September 2016 Grandlodge returned the US$1,500,000 purchase to Immuron. Grandlodge received no financial gains or benefits from this transaction. Foreign currency risk is measured by regular review of cash forecasts, monitoring the dollar amount and currencies that payment are anticipated to be paid in. The Company also considers the market fluctuations in relevant currencies to determine the level of exposure. If the level of exposure is considered by Management to be too high, then Management has authority to take steps to reduce the risk. Steps to reduce risk may include the acquisition of foreign currency ahead of the anticipated due date of an invoice, or may include negotiations with suppliers to make payment in our functional currency, or may include holding receipted foreign currency funds in a foreign currency denominated bank account to make future payments denominated in that same currency. Should Management determine that the Company consider taking out a hedge to reduce the foreign currency risk, they would need to seek Board approval. The Company conducts some activities outside of Australia which exposes it to transactional currency movements, where the Company is required to pay in a currency other than its functional currency. There has been no change in the manner the Company manages and measures its risk in the year ended 30 June 2018. The Company is exposed to fluctuations as noted in the table above. Analysis is conducted on a currency by currency basis using sensitivity variables. The Company has conducted a sensitivity analysis of the Company’s exposure to foreign currency risk. The analysis shows that if the Company’s exposure to foreign currency risk was to fluctuate as disclosed below and all other variables had remained constant, then the foreign currency sensitivity impact on the Company’s loss after tax and equity would be as follows: Trade and Other Payables 30 June 2018 (Higher) / Lower AUD$ 30 June 2017 (Higher) / Lower AUD$ AUD / USD: 2018 +8.00% (2017: +8.00%) 6,343 35,186 AUD / USD: 2018 -8.00% (2017:-8.00%) (6,343 ) (35,186 ) AUD / ISL: 2018 +11.00% (2017: +11.00%) 302 2,254 AUD / ISL: 2018 -11.00% (2017: -11.00%) (302 ) (2,254 ) Credit Risk The Company is exposed to credit risk via its cash and trade and other receivables. Credit risk is the risk that a counter-party will default on its contractual obligations resulting in a financial loss to the Company. To reduce risk exposure for the Company’s cash, it places them with high credit quality financial institutions. The Company’s major ongoing customers are the large pharmaceutical companies for the distribution of Travelan and other Hyperimmune products, and Government bodies for the receipt of GST refunds and Research and Development Tax Concession amounts due to the Company from the Australian Tax Office. The Company has a policy that limits the credit exposure to customers and regularly monitors its credit exposure. The Board believes that the Company does not have significant credit risk at this time in respect of its trade and other receivables. Regarding customers with over 30-day debt balance, management has maintained on-going communication with relevant counter parties in regard of repayment schedule, and concluded that there have been no changes to the initial assessment of credit risk. The Company has analyzed its trade receivables (excluding R&D receivable) below: 0 - 30 days AUD$ 31 - 60 days AUD$ 61 - 90 days AUD$ 90 days + AUD$ Total AUD$ 2018 Trade receivables 250,806 122,890 106,494 11,986 492,276 2017 Trade receivables 173,248 33,731 419 62,727 270,125 Liquidity Risk The Company is exposed to liquidity risk via its trade and other payables and its recurring and projected losses. Liquidity risk is the risk that the Company will encounter difficulty in raising funds to meet the commitments associated with its financial instruments. Responsibility for liquidity risk rests with the Board who manage liquidity risk by monitoring undiscounted cash flow forecasts and actual cash flows provided to them by the Company’s Management at Board meetings to ensure that the Company continues to be able to meet its debts as and when they fall due. Contracts are not entered into unless the Board believes that there is sufficient cash flow to fund the additional activity. The Board considers when reviewing its undiscounted cash flow forecasts whether the Company needs to raise additional funding from the equity markets. The Company has analyzed its trade and other payables below: 0 - 30 days AUD$ 31 - 60 days AUD$ 61 - 90 days AUD$ 90 days + AUD$ Total AUD$ 2018 Trade and other payables and notes payable 216,938 — — — 216,938 2018 Borrowings (see Note 18 for repayment terms) — — — — — 2018 Convertible notes (note 13 for repayment terms) — — — — — 2017 Trade and other payables and notes payable 1,074,569 102,546 72,052 77,395 1,326,562 2017 Borrowings (see Note 18 for repayment terms) n/a n/a n/a n/a 139,864 2017 Convertible notes (note 13 for repayment terms) n/a n/a n/a n/a 226,000 As of June 30, 2018, the Company maintained a cash balance of A$4,727,430 (fiscal year 2017: A$3,994,924). Additionally, the Company also recognised a total of A$1,683,305 (fiscal year 2017: A$1,768,237) in receivables, including a A$1,191,029 (fiscal year 2017: A$1,498,112) related to R&D Tax Concession. The 2017 R&D Tax concession was received in February 2018 and 2016 was received in November 2016. On this basis, even though the company has been in loss making position historically, management is satisfied that the Group is a going concern and are of the opinion that no asset is likely to be realized for an amount lower than the amount at which it is recorded in the Consolidated Statement of Financial Position as of June 20 2018.

Events after the Reporting Date

Events after the Reporting Date	12 Months Ended
	Jun. 30, 2018
Events After Reporting Date
Events after the Reporting Date	Note 21. Events after the Reporting Date On 29 June 2018, the Company announced to the market two major changes to the board. Effective 01 July, 2018, the Company appointed a non-executive director, Mr. Richard J Berman and the resignation of the joint company secretary Mr. Peter Vaughan. On 1 July 2018, the Company issued 1,000,000 unlisted employee stock options to a key management personnel, Dr. Jerry Kanellos. On 1 July 2018, the Company granted 2,000,000 unlisted options to Mr. Richard J Berman, subject to the shareholder approval. On 11 July 2018, the Company announced that the European Patent Office (EPO) has decided to grant a patent for the use of composition for the treatment of Non-alcoholic steatohepatitis (NASH). This patent (EPO Grant No. 2424890) is entitled “Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder”). This patent is due to Expire in April 2030, with potential for supplementary protection and extension of this monopoly. On 16 July 2018, the Company announced an update towards the research collaboration with the US Department of Defense Research going ahead. The report confirmed that Travelan pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completed, resulted in prevention of clinical shigellosis in 75% of Travelan treated NHPs compared to placebo. Studies were commissioned by the US Department of Defense to evaluate Travelan®’s ability to neutralise pathogenic bacteria of interest, including Campylobacter, ETEC and Shigella. No other matter or circumstances has arisen since 30 June 2018 that has significantly affected, or may significantly affect the Group’s operations, the results of those operations, or the Group’s state of affairs in future financial years.

Company Details

Company Details	12 Months Ended
	Jun. 30, 2018
Company Details
Company Details	Note 22. Company Details The registered office of the Company is: Level 3, 62 Lygon Street, Carlton, Victoria, Australia 3053. The principal place of business of the Company is: Unit 10, 25-37 Chapman Street, Blackburn, Victoria, Australia 3130.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2018
Summary Of Significant Accounting Policies
Basis of Consolidation	(a) Basis of Consolidation The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries) referred to as ‘the Group’ in the financial statements. Control is achieved where the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases. A list of controlled entities is contained in Note 11 to the financial statements. All controlled entities have a 30 June financial year-end. All intra-group transactions, balances, income and expenses are eliminated in full on consolidation. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with those policies applied by the parent entity. Subsidiaries are accounted for at cost in the parent entity. The results of subsidiaries acquired or disposed of during the year are included in profit or loss from the effective date of acquisition or up to the effective date of disposal, as appropriate.
Segment Reporting	(b) Segment Reporting The Company determines and presents operating segments using the ‘management approach’ where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Maker (‘CODM’). The CODM is responsible for the allocation of resources to operating segments and assessing their performance and provide the strategic direction and management oversight of the day to day activities of the entity in terms of monitoring results, providing approval for research and development expenditure decisions and challenging and approving strategic planning for the business.
Foreign Currency Translation	(c) Foreign Currency Translation Functional and Presentation Currency Items included in the financial statements are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The financial statements are presented in Australian dollars, which is the Company’s functional and presentation currency. Transactions and Balances Transactions in foreign currencies are translated into the functional currency using the rates of exchange ruling at the date of each transaction. At reporting date, amounts outstanding in foreign currencies are translated into the functional currency using the rate of exchange ruling at the end of the financial year. Refer to Note 3 for the foreign currency gains and losses recognized during the periods. Foreign exchange gains and losses that relate to borrowings are presented in the statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the statement of profit or loss and other comprehensive income on a net basis within Corporate Administration Costs. Immuron Inc., a subsidiary of the Group, has USD as its functional currency. Accordingly, this entity’s statement of comprehensive income and statement of financial position balances have been translated to the Group’s presentation currency (which is AUD$) at the reporting date. A gain arising from this translation of AUD$79,599 (2017: AUD$40,017) are recognized as Other Comprehensive Income for the year.
Revenue Recognition	(d) Revenue Recognition Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of returns, trade allowances, rebates and amounts collected on behalf of third parties. The Company recognizes revenue when the amount of the revenue can be reliably measured, it is probable that the future economic benefits will flow to the entity and specific criteria have been met for each of the activities as described below. The amount of the revenue is not considered to be reliably measured until all contingencies relating to the sale have been resolved. The following specific revenue criteria must be met before revenue is recognized: Sale of Goods and services Significant risks and rewards of ownership of goods has passed to the buyer and an invoice for the goods or services is issued Interest Interest income is recognized using the effective interest rate method R & D Tax Refund Income is recognized in the year the research and development expenses were incurred We engaged experienced advisors (KPMG) to determine and evaluate the advanced findings of the R&D activities, which includes determining and evaluating the eligibility of R&D related expenditure to support our submission of the R&D Tax refund claim. As at 30 June 2018, the recorded income in relation to the R&D was A$ 1,849,123 and the receivable for financial period 2018 was accrued in the statement of financial position was A$ 1,191,029.
Government Grants	(e) Government Grants Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received, and the Company will comply with all attached conditions. Government grants relating to costs to be incurred are deferred or accrued such that they are recognized in the statement of profit or loss and other comprehensive income over the period necessary to match them with the costs that they are intended to compensate.
Income Tax	(f) Income Tax The income tax expense or revenue for the period is the tax payable or tax rebate receivable on the current period’s taxable income adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax base of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses. Deferred income tax is provided in full, using the liability method on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. However, the deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither the accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax is realized or the deferred income tax liability is settled. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Current and deferred tax balances attributable to amounts recognized directly in equity are also recognized directly in equity.
Impairment of Assets	(g) Impairment of Assets Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use.
Cash and Cash Equivalents	(h) Cash and Cash Equivalents For presentation purposes, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short- term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts.
Trade Receivables	(i) Trade Receivables Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest rate method, less provision for impairment. Trade receivables are due for settlement no more than 30 days from the date of recognition. Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off. A provision for impairment of trade receivables is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of receivables. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganization and default or delinquency in payment (more than 30 days overdue) are considered indicators that the trade receivable is impaired. The amount of the provision is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. Cash flows relating to short term receivables are not discounted if the effect of discounting is immaterial. The amount of the provision is recognized in the statement of profit or loss and other comprehensive income.
Inventories	(j) Inventories Raw materials, work in progress and finished goods are stated at the lower of cost and net realizable value. Cost comprises direct materials, freight and import duty. The Company classifies inventory as a current asset for amounts it expects to sell or consume within its normal operating cycle. Costs are assigned to individual items of finished goods inventory on basis of weighted average costs. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.
Plant & Equipment	(k) Plant & Equipment Plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Repairs and maintenance are charged to the statement of profit or loss and other comprehensive income during the financial period in which they are incurred. Depreciation on assets is calculated using the straight-line method to allocate their cost, net of their residual values, over their estimated useful lives, as follows: - Plant & Equipment (3 - 15 years) - Computer Equipment (2 - 4 years) - Furniture & Fittings (3 - 15 years) The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, annually. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount (Note 1(g)). Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in the statement of profit or loss and other comprehensive income.
Intangible Assets	(l) Intangible Assets (i) Research & Development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the statement of profit or loss and other comprehensive income as an expense when it is incurred. Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalized if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits and adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the statement of profit or loss and other comprehensive income as an expense as incurred.
Trade and Other Payables	(m) Trade and Other Payables These amounts represent liabilities for goods and services provided to the entity prior to the end of the financial year and which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade payables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest rate method.
Employee Benefits	(n) Employee Benefits (i) Short-term obligations Liabilities for wages and salaries, annual leave and long service leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. (ii) Other long-term employee benefits obligations The liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. The obligations are presented as current liabilities in the Statement of financial position if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur. (iii) Retirement benefit obligations Contributions to the defined contribution superannuation funds are recognized as an expense as they become payable. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. (iv) Share-based payments Share-based compensation benefits may be provided through the issue of fully paid ordinary shares under the Immuron Employee Share and Option Plan (“ESOP”). Options are also granted to employees and consultants in accordance with the terms of their respective employment and consultancy agreements. Any options granted are made in accordance with the terms of the Company’s ESOP. The fair value of options granted under employment and consultancy agreements are recognized as an employee benefit expense with a corresponding increase in equity. The fair value is measured at grant date and recognized over the period during which the employees become unconditionally entitled to the options. The fair value at grant date is determined using a Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the vesting and performance criteria, the impact of dilution, the non-tradeable nature of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the option. The fair value of the options granted excludes the impact of any non-market vesting conditions (for example, profitability and sales growth targets). Non-market vesting conditions are included in assumptions about the number of options that are expected to become exercisable. At each reporting date, the entity revises its estimate of the number of options that are expected to become exercisable. The employee benefit expense recognized each period takes into account the most recent estimate. The impact of the revision to original estimates, if any, is recognized in the statement of profit or loss and other comprehensive in come with a corresponding adjustment to equity. Upon the exercise of options, the balance of the share-based payments reserve relating to those options is transferred to contributed equity. (v) Termination benefits Termination benefits are payable when employment is terminated before the normal retirement date, or when an employee accepts voluntary redundancy in exchange for these benefits. The Company recognises termination benefits when it is demonstrably committed to either terminating the employment of current employees according to a detailed formal plan without possibility of withdrawal or providing termination benefits as a result of an offer made to encourage voluntary redundancy. Benefits falling due more than 12 months after reporting date are discounted to present value.
Interest Bearing Loans and Borrowings	(o) Interest Bearing Loans and Borrowings Generally, loans and borrowings are initially recognized at cost, being the fair value of the consideration received net of issue costs associated with the borrowing. After initial recognition, interest bearing loans and borrowings are subsequently measured at amortized cost using the effective interest method. Amortized cost is calculated by taking into account any issue costs and any discount or premium on settlement. The component of the convertible notes that were issued in connection with the February 2016 financing arrangement that exhibits characteristics of a liability is recognised as a liability in the statement of financial position. On the date of issuance and each subsequent reporting period, the Company records the entire hybrid instrument as measured at fair value through profit and loss as the embedded derivative does significantly modify the cash flows under the contract. The associated transaction costs have also been expensed as incurred and are recorded as Finance costs in the Statement of Profit or Loss and Other Comprehensive Income. Fair Value of Convertible Notes The convertible notes were measured and disclosed as a level 3 instrument, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, as defined below: ● Level 1: Quoted price (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date ● Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset and liability, either directly or indirectly ● Level 3: Unobservable inputs for the asset or liability No transfers between the levels of the fair value hierarchy occurred during the current year.
Contributed Equity	(p) Contributed Equity Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction from the proceeds.
Earnings per Share	(q) Earnings per Share (i) Basic earnings per share Basic earnings per share is calculated by dividing the profit or loss attributable to equity holders of the Company, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the full year, adjusted for bonus elements in ordinary shares issued during the full year. (ii) Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.
Goods and Services Tax (GST)	(r) Goods and Services Tax (GST) Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST recoverable or payable. The net amount of GST recoverable from, or payable to, the taxation authorities is included with other receivable or payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flow arising from investing or financing activities which are recoverable for, or payable to, the taxation authorities are presented as operating cash flow.
Leases	(s) Leases Leases in which a significant portion of the risk and reward of ownership are not transferred to the Company as lessee are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the statement of profit or loss and other comprehensive income on a straight-line basis over the period of the lease. Critical Accounting Estimates and Judgments Management evaluates estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both internally and externally. (i) Share-based Payments The value attributed to share options and remunerations shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the value of volatility of the price of the underlying shares. Refer to note 19 for more details. (ii) Impairment of Inventories The provision for impairment of inventories assessment requires a degree of estimation and judgment. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventories and in particular the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. (iii) Provision for employee benefits Provision for employee benefits represents amounts accrued for annual leave and long service leave. The current portion for this provision includes the total amount accrued for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the required period of service. (iv) R&D tax incentive The Group’s research and development activities are eligible under an Australian Government tax incentive for eligible expenditure from 1 July 2011. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. For the year ended 30 June 2018 the Group has recorded in other income of $1,849,123 (2017: $1,575,315) to recognize this amount which relates to this financial year. (v) Inventory split The Company’s policy is to reassess the classification of inventory on a periodic basis to determine if the inventory have a longer shelf-life and to assess whether there exists an alternative market for the Colostrum powder (which remains a majority of the inventory). During the current financial period, management have performed an assessment on its raw materials and its utilization within 12 months from reporting date and have determined $198,585 of raw materials relating to Colostrum expected to be consumed with 12 months and remaining balance of $2,171,867 expected to be consumed after 12 months from reporting date. During the year ended June 30, 2018, management determined that a portion of its inventory should be reclassified on a prospective basis as a noncurrent asset as a result of a strategic decision made by management in the intended use of its inventory. The Company decided to terminate all plans to sell the colostrum powder to secondary markets as a result of the continued scientific evidence supporting an extended shelf life. The extended shelf life provides the Company with the assurance that colostrum will be consumed through the production of its current Travelan and Protectyn products throughout future reporting periods. (vi) Fair value measurement hierarchy The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections where applicable. The fair value of the convertible notes classified as level 3 are determined by the use of valuation model. These include discounted cash flow analysis and the use of observable inputs that required significant adjustments based on unobservable inputs. As at June 30, 2017, management has assessed the terms of the convertible notes and determined that in their view the fair value of the debt component is equal to the proceeds such that there is no residual amount to be allocated to an equity component. In making this determination, management is of the view that the value of the consideration received, net of costs, provided reliable evidence of the fair value of the debt component of the convertible notes. Fair value has been determined by the income approach based on a discounted cash flow analysis, with the most significant inputs being the discount rate that reflects the investors credit risk. A slight increase or decrease in the discount rate used would not be material to the financial statements. Reconciliation of level 3 fair value measurements: Convertible notes/debentures AUD$ Balance at 30 June 2016 1,128,117 - Issue — - Change in fair value (*) — - Repayments (902,117 ) Balance at 30 June 2017 (Note 13) 226,000 (*) These amounts are recorded in the Finance Costs on the Statement of Profit or Loss and Other Comprehensive Income.
Comparatives	(t) Comparatives Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to reclassify the employee benefit obligations within the Consolidated Statements Financial Position for fiscal year ended September 30, 2017 to seek consistent presentation with the current financial period.

Revenue and other income (Table

Revenue and other income (Tables)	12 Months Ended
	Jun. 30, 2018
Revenue And Other Income
Schedule of revenue and other income	30 June 2018 30 June 2017 30 June 2016 AUD$ AUD$ AUD$ Revenue Revenue from Operating Activities Sale of goods 1,842,909 1,396,197 1,001,077 Total Revenue from Operating Activities 1,842,909 1,396,197 1,001,077 Other Income Other income 40 30,672 14,010 Interest income 1,238 8,386 12,165 R&D tax concession refund 1,849,123 1,575,315 1,512,840 Other Income from Non-Operating Activities 1,850,401 1,614,373 1,539,015 Total Revenue and Other Income 3,693,310 3,010,570 2,540,092

Expenses (Tables)

Expenses (Tables)	12 Months Ended
	Jun. 30, 2018
Expenses Abstract
Schedule of expenses	30 June 2018 30 June 2017 30 June 2016 Expenses a) Consulting, Employee and Director Expenses Consulting expenses — — 46,775 Wages and salaries expenses 885,197 905,819 956,737 Superannuation and other employee related expenses 153,795 39,664 32,537 Director expenses 285,331 221,373 197,713 Share- based payments 59,975 522,665 1,606,275 Total Consulting, Employee and Director Expenses 1,384,298 1,689,521 2,840,037 b) Corporate Administrative Costs Audit and accounting fees 222,973 146,007 62,825 Insurances 277,888 150,502 100,609 Foreign exchange (gain) / losses (258,767 ) 238,985 217,904 Corporate administration costs 1,094,422 846,315 939,232 Total Corporate Administrative Costs 1,336,516 1,381,809 1,320,570

Income Tax Benefit (Tables)

Income Tax Benefit (Tables)	12 Months Ended
	Jun. 30, 2018
Income Tax Benefit
Schedule of income tax benefit	30 June 2018 AUD$ Profit from continuing operations before income tax expense (3,010,929 ) Tax at the Australian tax rate of 27.5% (2017 - 27.5%, 2016 – 30%) (828,005 ) Tax effect of amounts which are not deductible (taxable) in calculating taxable income: Non-deductible amounts associated with R&D rebates (508,509 ) Non-allowable expenses 796,398 Deferred tax assets relating to tax losses not recognized 540,116 Income tax expense —

Key Management Personnel Comp_2

Key Management Personnel Compensation (Tables)	12 Months Ended
	Jun. 30, 2018
Key Management Personnel Compensation
Schedule of key management personnel compensation	The aggregate compensation made to Directors and Other Key Management Personnel of the Company is set out below: 30 June 2018 AUD$ 30 June 2017 AUD$ 30 June 2016 AUD$ Key Management Personnel Compensation Short-term employee benefits 570,256 681,666 652,514 Post-employment benefits 32,087 25,947 26,004 Share-based payments 59,975 353,670 1,606,275 Total Key Management Personnel Compensation 662,318 1,061,283 2,284,793

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Jun. 30, 2018
Loss Per Share
Schedule of basic and diluted loss per share	30 June 2018 30 June 2017 30 June 2016 AUD$ AUD$ AUD$ Basic/Diluted loss per share (in cents) 2.300 6.400 9.248 a) Net loss used in the calculation of basic and diluted loss per share 3,010,929 6,804,154 7,068,767 b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share 133,660,556 105,866,110 76,435,993 * * This amount includes 182,169 of weighted average shares for ordinary shares in relation to the A$4,511,378 received in capital raising that was not issued as of 30 June 2016.

Cash (Tables)

Cash (Tables)	12 Months Ended
	Jun. 30, 2018
Cash and cash equivalents [abstract]
Schedule of balances under cash	30 June 2018 30 June 2017 Cash at Bank and in hand: Cash at bank and in hand 4,727,430 3,994,924 Total Cash 4,727,430 3,994,924

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	12 Months Ended
	Jun. 30, 2018
Trade And Other Receivables
Schedule of trade and other receivables	30 June 2018 AUD$ 30 June 2017 AUD$ Current Trade receivables* 492,276 270,125 Accrued income** 1,191,029 1,498,112 Total Trade and Other Receivables 1,683,305 1,768,237 * All trade receivables are non-interest bearing. ** Primarily comprises of receivables from the Australian Tax Office in relation to R&D tax concession for the year.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jun. 30, 2018
Inventories Abstract
Schedule of inventories	30 June 2018 30 June 2017 Current Inventory Raw materials 198,585 1,793,882 Work in Progress 33,625 48,425 Finished goods 265,692 357,478 Prepaid inventory and supplies — 136,342 Total Inventory 497,902 2,336,127
Schedule of non current inventories	During the current financial period, management has performed an assessment on its raw materials and utilization within 12 months from reporting date and have determined AUD$198,585 of raw materials relating to Colostrum will be consumed within 12 months and the remaining balance of AUD$2,171,867 will be consumed after 12 months from reporting date. 30 June 2018 30 June 2017 Non-Current Inventory Raw materials 2,171,867 — Total Non-Current Inventory 2,171,867 168,336

Controlled Entities (Tables)

Controlled Entities (Tables)	12 Months Ended
	Jun. 30, 2018
Controlled Entities
Schedule of subsidiaries	The country of incorporation or registration is also their principal place of business. Country of Percentage of Ownership Incorporation 30 Jun 2018 30 Jun 2017 Parent Entity: Immuron Limited Australia — — Subsidiaries of Immuron Limited: Immuron Inc. USA 100 % 100 % Anadis EPS Pty Ltd Australia 100 % 100 % IMC Canada Ltd. Canada 100 % 0 %

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Jun. 30, 2018
Trade and other payables [abstract]
Schedule of trade and other payables	30 June 2018 30 June 2017 AUD$ AUD$ Current Trade payables 216,938 699,530 Accrued expenses 435,280 568,988 Other payables 37,108 21,871 Total 689,326 1,290,389

Other Liabilities (Tables)

Other Liabilities (Tables)	12 Months Ended
	Jun. 30, 2018
Other Liabilities
Schedule of other liabilities	30 June 2018 30 June 2017 AUD$ AUD$ Other Liabilities Convertible Notes* — 226,000 Deferred Revenue** — 19,139 Borrowings*** — 139,864 Total — 385,003 (*) Convertible Notes: On 17 February 2016, the Company secured A$1,700,000 in funding with a New York-based Investment Fund. The facility was used to fund the immediate start of the clinical phase for IMM-529 in Clostridium difficile (**) Deferred Revenue: This amount represents amounts billed by the Company for undelivered goods. (***) Borrowings: The Company has financed A$162,457 for its insurance policies during the year ended June 30, 2017. Principal and interest (A$8,561) is to be repaid monthly by Immuron over a 11-month term. During the financial year 2018, the outstanding borrowings were repaid by the Company.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2018
Commitments And Contingencies
Schedule of Lease commitments not recognized in the financial statements	30 June 2018 AUD$ Lease commitments not recognized in the financial statements: - not later than 12 months 19,470 - between 1 and 5 years — Total 19,470

Contributed Equity (Tables)

Contributed Equity (Tables)	12 Months Ended
	Jun. 30, 2018
Contributed Equity
Schedule of contributed equity	30 June 2018 30 June 2017 30 June 2016 No. AUD$ No. AUD$ No. AUD$ Fully Paid Ordinary Shares (No par value) Balance at Beginning of year 130,041,417 53,632,995 80,099,646 45,633,354 74,964,232 40,335,347 Capital consolidation (40:1) — — — — Shares issued during the year 14,736,789 5,472,200 49,941,771 9,965,323 5,135,414 1,721,789 Shares to be issued(*) — — — 4,511,378 Transactions costs (733,152 ) — (2,037,557 ) — (135,160 ) Cancellation of shares (2,000,000 ) — — — — — Treasury shares — — — — — (800,000 ) Movement to Retained Earnings — — — 71,875 — — Total Contributed Equity 142,778,206 58,372,043 130,041,417 53,632,995 80,099,646 45,633,354 (*) As at 30 June 2016, the Company was committed to issue 18,045,512 ordinary shares in relation to the A$4,511,378 received in capital raising.
Schedule of securities issued	During the Full Year ended 30 June 2018, the Company issued the following securities: Date Details No. Issue Price AUD$ Total Value AUD$ 28-Jul-17 Issue of Equity for the repayment of Sea Otter 16th payment of Convertible Note 399,045 0.19 75333 13-Nov-17 Issue of Shares to Grandlodge 875,000 0.16 140,000 15-Mar-18 Private Placement to US Investment Fund 13,162,744 0.39 5,161,585 15-Mar-18 Exercise of NASDAQ Warrants (IMRNW) 300,000 0.32 95,282 Total 2018 Movement 14,736,789 5,472,200 During the Full Year ended 30 June 2017, the Company issued the following securities: Date Details No. Issue Price Total Value 7 Jul 2016 Right issue* 18,045,512 — — 7 Jul 2016 Right issue 3,275,466 0.25 818,867 29 Sep 2016 Right issue to oversubscribes and private placement 3,968,916 0.25 992,229 2 Dec 2016 Shares under ESOP – for 6 months service (vesting monthly) 251,877 0.245 61,710 9 Jun 2017 Shares issued on NASDAQ (equivalent to 610,000 ADSs)** 24,400,000 0.332 8,092,517 Total 2017 Movement 49,941,771 9,965,323 (*) As at 30 June 2016, the Company was committed to issue 18,045,512 of ordinary shares in relation to the A$4,511,378 received in capital raising. These shares were subsequently issued to respective holders on 7 July 2016. 2,418,129 of these new fully paid ordinary shares were issued to Grandlodge on the same terms and conditions as all other subscribers. (**) Grandlodge participated in our NASDAQ IPO and acquired 32,707 ADRs and 32,707 Warrants. During the Full Year ended 30 June 2016, the Company issued the following securities: Date Details No. Issue Price AUD$ Total Value AUD$ 18 Sep 2015 Exercise of IMCAI Unlisted Options 218,750 0.376 82,250 30 Sep 2015 Exercise of IMCAI Unlisted Options 93,750 0.376 35,250 19 Oct 2015 Exercise of IMCAI Unlisted Options by Grandlodge 556,000 0.376 209,056 13 Nov 2015 Exercise of IMCAI Unlisted Options 41,666 0.376 15,667 27 Nov 2015 Issue of Shares in lieu of cash payment for services as per Resolution 4 of the Annual General Meeting (AGM) held on 25 Nov 2015 546,875 0.160 87,500 24 Feb 2016 Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016 294,118 0.340 100,000 24 Feb 2016 Issue of fully paid escrow shares as security for any repayment default of the Convertible Loan in accordance with executed funding agreement with a New York based Investment fund provider and announced to the ASX on 17 Feb 2016 2,000,000 0.400 800,000 13 Apr 2016 Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016 326,797 0.306 100,000 18 Apr 2016 First repayment of Convertible Notes Security in accordance with executed funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016 241,764 0.312 75,333 16 May 2016 Exercise of IMCAI Unlisted Options 150,000 0.276 41,400 16 May 2016 Second repayment of Convertible Notes Security in accordance with executed funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016 265,694 0.284 75,333 31 May 2016 Issue of Shares in lieu of cash payment for services received 400,000 0.250 100,000 30 Jun 2016 Shares to be Issued from Capital Raising as at 30 June 2016 — — 4,511,378 Total 2016 Movement 5,135,414 6,233,167

Reserves (Tables)

Reserves (Tables)	12 Months Ended
	Jun. 30, 2018
Reserves Abstract
Schedule of option reserves and foreign currency translation reserve	The reserve recognizes option reserves which are the expense recognized in respect of share-based payments, and foreign currency translation reserve arising from translation of foreign subsidiary. 30 June 2018 30 June 2017 30 June 2016 No. AUD$ No. AUD$ No. AUD$ Options over Fully Paid Ordinary Shares Balance at Beginning of year 63,690,523 2,434,135 9,937,629 2,132,301 7,188,676 560,646 Capital consolidation (40:1) — — — — Options issued during the year 8,424,157 156,392 56,002,894 136,784 7,425,532 285,600 Granted options to be issued(*) — — — — Options exercised during the year (300,000 ) — — — (1,060,166 ) (71,875 ) Expense of vested options — 59,975 — 333,950 — 1,606,275 Lapse of unexercised options (465,500 ) (463 ) (2,250,000 ) (168,900 ) (3,616,413 ) (248,345 ) Closing Balance 71,349,180 2,650,039 63,690,523 2,434,135 9,937,629 2,132,301 Foreign currency translation reserve Opening balance 36,282 (3,735 ) (12,581 ) Movement during the year — (79,599 ) — 40,017 — 8,846 Closing balance — (43,317 ) 36,282 (3,735 ) Total Reserves 71,349,180 2,606,722 63,690,523 2,470,417 9,937,629 2,128,566 (*) On 9 December 2016, the Company issued 1 million options exercisable at A$0.50 per option expiring on April 1, 2017 to an employee under the Company’s ESOP following the successful completion of the related milestone pertaining to a minimum recruitment of 100 patients into the Company’s NASH Phase 2 clinical trial
Schedule of options issued	During the Full Year ended 30 June 2018, the Company issued the following options: Date Details No. AUD$ AUD$ 15-Mar-18 Issue of options- Free-attaching 3 options for every 5 new shares as a part of the capital raise 7,897,647 — — 15-Mar-18 Issue of options - Broker shares as part of placement fee 526,510 0.3 156,392 Total 2018 Movement 8,424,157 156,392 During the Full Year ended 30 June 2017, the Company issued the following options: Date Details No. AUD$ AUD$ 7 Jul 2016 Right issue** 18,045,512 — — 7 Jul 2016 Right issue 3,275,466 — — 29 Sep 2016 Right issue to oversubscribes and private placement 3,968,916 — — 9 Dec 2016 Unlisted options in lieu of services 200,000 0.143 28,620 9 Jun 2017 Options issued to cover equivalent of 610,000 warrants on issue with NASDAQ 24,400,000 0.00033 8,101 9 Jun 2017 Options issued to cover equivalent of 35,075 warrants on issue with NASDAQ 1,403,000 0.00033 463 13 Jun 2017 Options issued to cover equivalent of 91,500 warrants on issue with NASDAQ 3,660,000 0.00033 1,215 22 Jun 2017 Unlisted options in lieu of services 1,050,000 0.094 98,385 Total 2017 Movement 56,002,894 136,784 (**) As of 30 June 2016, the Company was committed to issue 18,045,512 options in relation to the A$4,511,378 received in capital raising. These options were subsequently issued to respective holders on 7 July 2016. 2,418,129 of these options were issued to Grandlodge on the same terms and conditions as all other subscribers. On 22 June 2017, the Company issued Professor Ravi Savarirayan, a Non-Executive Director of Immuron Limited, 1,000,000 unlisted options exercisable at A$0.50 on or before 27 Nov 2019. During the Annual General Meeting in 2018, the shareholders approved the issuance of the options to Ravi Savarirayan. During the Full Year ended 30 June 2016, the Company issued the following options: Date No. Issue Price AUD$ Total Value AUD$ 27 Nov 2015 Issue of Unlisted Options in lieu of cash payment for additional services as per Resolution 5A - 5D of the AGM held on 25 Nov 2015 6,000,000 — 1,606,275 18 Feb 2016 Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016 1,000,000 0.186 185,600 31 May 2016 Issue of Unlisted Options in lieu of cash payment for services received 425,532 0.235 100,000 Total 2016 Movement 7,425,532 1,891,875

Segments Reporting (Tables)

Segments Reporting (Tables)	12 Months Ended
	Jun. 30, 2018
Segments Reporting
Segment of interest expenses from financing activities and depreciation	Research & Development HyperImmune Products Unallocated Corporate Total 30 June 2018 AUD$ AUD$ AUD$ AUD$ Segment Revenue & Other income Revenue from external customers — 1,842,909 — 1,842,909 R&D tax concession refund 1,849,123 — 1,238 1,850,361 Other income — 40 — 40 Total Segment Revenues & Other income 1,849,123 1,842,949 1,238 3,693,310 Segment Expenses Depreciation — — (5,047 ) (5,047 ) Finance costs — — (18,857 ) (18,857 ) Share-based payments — — (59,975 ) (59,975 ) Other operating expenses (2,257,224 ) (832,661 ) (3,530,475 ) (6,620,360 ) Total Segment Expenses (2,257,224 ) (832,661 ) (3,614,354 ) (6,704,239 ) Income Tax Expenses — — — — (Loss)/Profit for the Period (408,101 ) 1,010,288 (3,613,116 ) (3,010,929 ) Assets Segment assets 1,191,029 3,162,045 4,889,614 9,242,688 Total Assets 1,191,029 3,162,045 4,889,614 9,242,688 Liabilities Segment liabilities (174,434 ) (26,009 ) (602,895 ) (803,338 ) Total Liabilities (174,434 ) (26,009 ) (602,895 ) (803,338 ) Research & Development HyperImmune Products Unallocated Corporate Total 30 June 2017 AUD$ AUD$ AUD$ AUD$ Segment Revenue & Other income Revenue from external customers — 1,396,197 — 1,396,197 R&D tax concession refund 1,575,315 — — 1,575,315 Interest income — — 8,386 8,386 Other income 25,000 5,672 — 30,672 Total Segment Revenues & Other income 1,600,315 1,401,869 8,386 3,010,570 Segment Expenses Depreciation — — (4,922 ) (4,922 ) Finance costs — — (24,483 ) (24,483 ) Share-based payments (188,481 ) — (334,184 ) (522,665 ) Other operating expenses (4,805,874 ) (1,017,169 ) (3,439,611 ) (9,262,654 ) Total Segment Expenses (4,994,355 ) (1,017,169 ) (3,803,200 ) (9,814,724 ) Income Tax Expenses — — — — (Loss)/Profit for the Period (3,394,040 ) 384,700 (3,794,814 ) (6,804,154 ) Assets Segment assets 1,498,112 2,585,755 4,202,624 8,286,491 Total Assets 1,498,112 2,585,755 4,202,624 8,286,491 Liabilities Segment liabilities (514,326 ) (330,218 ) (867,021 ) (1,711,565 ) Total Liabilities (514,326 ) (330,218 ) (867,021 ) (1,711,565 ) Research & Development HyperImmune Products Unallocated Corporate Total 30 June 2016 AUD$ AUD$ AUD$ AUD$ Segment Revenue & Other income Revenue from external customers — 1,001,077 — 1,001,077 R&D tax concession refund 1,512,840 — — 1,512,840 Interest income — — 12,165 12,165 Other income — 10,200 3,810 14,010 Total Segment Revenues & Other income 1,512,840 1,011,277 15,975 2,540,092 Segment Expenses Depreciation — — (3,892 ) (3,892 ) Finance costs — — (156,000 ) (156,000 ) Share-based payments — — (2,079,375 ) (2,079,375 ) Other operating expenses (3,623,961 ) (570,183 ) (3,175,448 ) (7,369,592 ) Total Segment Expenses (3,623,961 ) (570,183 ) (5,414,715 ) (9,608,859 ) Income Tax Expenses — — — — (Loss)/Profit for the Period (2,111,121 ) 441,094 (5,398,740 ) (7,068,767 ) Assets Segment assets 1,512,840 2,318,860 4,995,784 8,827,484 Total Assets 1,512,840 2,318,860 4,995,784 8,827,484 Liabilities Segment liabilities (769,434 ) (538,806 ) (2,578,681 ) (3,886,921 ) Total Liabilities (769,434 ) (538,806 ) (2,578,681 ) (3,886,921 )
Schedule of major customers	During the years ended 30 June 2018, 2017 and 2016, the Company had the following major customers (and their respective contribution to the Group’s total revenue): 2018 2017 2016 Customer A 31 % 13 % 16 % Customer B 25 % 34 % 43 % Customer C 12 % 15 % 22 % Customer D 10 % 15 % * Customer E * 10 % * * Less than 10% of revenue for the respective year.

Cash Flow Information (Tables)

Cash Flow Information (Tables)	12 Months Ended
	Jun. 30, 2018
Cash Flow Information
Schedule of reconciliation of cash flow from operations with loss after income tax	30 June 2018 AUD$ 30 June 2017 AUD$ 30 June 2016 AUD$ Net Loss for the Year (3,010,929 ) (6,804,154 ) (7,068,767 ) Non-Cash Add depreciation expense 5,047 4,922 3,892 Add change in fair value and interest accrued on borrowings — 8,561 178,401 Add back equity issued for non-cash consideration* — — 187,500 Add back share based payments expense 242,950 522,665 1,891,875 Changes in Working Capital Add decreases / (increases) in current trade and other receivables 84,932 7,396 (84,004 ) Add decreases / (increases) in other current assets 26,561 69,034 (30,015 ) Add (increases) in inventory (333,642 ) (280,060 ) (909,800 ) Add (decreases) / increases in current trade and other payables and deferred revenue (620,202 ) (559,452 ) 672,582 Add (decrease) increase in provisions 77,839 — — (3,527,444 ) (7,031,088 ) (5,158,336 ) * The cost of A$187,500 relates to issue of shares worth A$87,500 in lieu of cash payments for services to Advanced Clinical Systems International as per resolution 4 of the AGM held on 25 November 2015. Additionally, shares worth A$100,000 were issued to The CFO Solution in lieu of services on 31 May 2016.

Share-based Payments (Tables)

Share-based Payments (Tables)	12 Months Ended
	Jun. 30, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of other options/warrants issued	30 June 2018 30 June 2017 30 June 2016 Number of Weighted Number of Weighted Number of Weighted Outstanding at the beginning of the year 56,378,023 0.440 1,875,129 0.561 4,332,526 0.400 Capital consolidation (40:1) — — — — Options granted during the year 8,424,157 0.470 54,752,894 0.430 1,425,532 0.549 Options exercised (300,000 ) — — (910,166 ) 0.376 Lapse of unexercised options (465,500 ) 1.550 (250,000 ) 0.460 (2,972,763 ) 0.376 Options Outstanding at End of the Year 64,036,680 0.470 56,378,023 0.440 1,875,129 0.561 Options Exercisable at the End of the Year 64,036,680 0.470 56,378,023 0.440 1,875,129 0.561
Schedule of vesting terms of options	The following summarizes information about options held by employees, Directors and third parties as at 30 June 2018 (To add Rows): Issue Date Number of Options Vesting Conditions Expiry Date Exercise Price AUD$ 29-Jun-12 14,493 Nil 30-Nov-21 AUD$ 1.944 29-Jun-12 29,668 Nil 17-Jan-22 AUD$ 1.876 3-Mar-14 15,380 Nil 28-Feb-19 AUD$ 1.892 29-May-14 140,056 Nil 28-May-19 AUD$ 0.300 27-Nov-15 6,000,000 See below 27-Nov-19 AUD$ 0.500 18-Feb-16 1,000,000 Nil 24-Feb-19 AUD$ 0.570 31-May-16 425,532 Nil 27-Nov-19 AUD$ 0.500 7-Jul-16 25,289,894 Nil 30-Nov-19 AUD$ 0.550 9-Dec-16 200,000 Nil 27-Nov-19 AUD$ 0.500 9-Jun-17 24,400,000 Nil 13-Jun-22 AUD$ 0.326 13-Jun-17 3,660,000 Nil 13-Jun-22 AUD$ 0.326 22-Jun-17 1,050,000 Nil 1-Oct-18 AUD$ 0.500 22-Jun-17 1,000,000 Nil 27-Nov-19 AUD$ 0.500 15-Mar-18 7,897,647 Nil 15-Mar-23 AUD$ 0.468 15-Mar-18 526,510 Nil 15-Mar-23 AUD$ 0.585
Schedule of deemed valuation of options	November 2015 Options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date As per above Dividend yield — Expected volatility 100 % Risk-free interest rate 2.11 % Expected life of option (years) 4 years Option exercise price AUD$ 0.5000 Weighted average share price at grant date AUD$ 0.465 Value per option AUD$ 0.3186 February 2016 Options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date N/A Dividend yield — Expected volatility 97 % Risk-free interest rate 1.73 % Expected life of option (years) 3 years Option exercise price AUD$ 0.5700 Weighted average share price at grant date AUD$ 0.36 Value per option AUD$ 0.1856 May 2016 Options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date N/A Dividend yield — Expected volatility 84 % Risk-free interest rate 2.11 % Expected life of option (years) 4 years Option exercise price AUD$ 0.5000 Weighted average share price at grant date AUD$ 0.41 Value per option AUD$ 0.235 December 2016 Options Pursuant to an agreement entered between the Company and a consultant on April 1, 2015, the Company granted 1,000,000 options, which were issued and vested on 9 December 2016, and each option entitles the holder to purchase one ordinary share of the Company at an exercise price of A$0.500. These options were issued and vested following the successful completion of related milestone pertaining to a minimum recruitment of 100 patients into the Company’s NASH Phase 2 clinical trial. The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date N/A Dividend yield — Expected volatility 100 % Risk-free interest rate 1.69 % Expected life of option (years) 3.17 years Option exercise price AUD$ 0.5000 Weighted average share price at grant date AUD$ 0.285 Value per option AUD$ 0.1431 June 2017 Options The following table lists the inputs to the model used to determine the weighted average value of the options expensed during the year: Vesting date N/A Dividend yield — Expected volatility 100 % Risk-free interest rate 1.69 % Expected life of option (years) 1.33 years Option exercise price AUD$ 0.5000 Weighted average share price at grant date AUD$ 0.315 Value per option AUD$ 0.0937
Directors [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movement in number of stock options outstanding and weighted average exercise price	The following table illustrates the number and weighted average exercise price of and movement in share options issued to directors during the year: 30 June 2018 30 June 2017 30 June 2016 Number of Weighted Number of Weighted Number of Weighted Outstanding at the beginning of the year 6,000,000 0.500 7,000,000 0.456 1,000,000 0.456 Capital consolidation (40:1) — — — — Options granted during the year — — 6,000,000 0.500 Lapse of unexercised options — — (1,000,000 ) 0.460 — — Options Outstanding at End of the Year 6,000,000 0.500 6,000,000 0.500 7,000,000 0.494 Options Exercisable at the End of the Year 6,000,000 0.500 5,000,000 0.500 1,000,000 0.456
ESOP [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of movement in number of stock options outstanding and weighted average exercise price	The following table illustrates the number and weighted average exercise price of and movement in share options issued under the scheme during the year: 30 June 2018 30 June 2017 30 June 2016 Number of Weighted Number of Weighted Number of Weighted Outstanding at the beginning of the year 1,312,500 0.550 1,062,500 1.560 1,856,150 0.440 Capital consolidation (40:1) — — — — Options granted during the year — — 1,250,000 0.500 — — Granted options to be issued* — — — — Options exercised — — (150,000 ) 0.276 Lapse of unexercised options — — (1,000,000 ) 0.500 (643,650 ) 0.276 Options Outstanding at End of the Year 1,312,500 0.550 1,312,500 0.550 1,062,500 0.562 Options Exercisable at the End of the Year 1,312,500 0.550 1,312,500 0.550 62,500 1.556

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2018
Related party transactions [abstract]
Disclosure of transactions between related parties	30 June 2018 30 June 2017 30 June 2016 Short-term Loan from Grandlodge Capital Pty Ltd Grandlodge Capital Pty Ltd (Grandlodge) is an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou. Mr David Plush is also an owner of Grandlodge, and its associated entities. On 1 December 2015, 6 June 2016 and 9 May 2017, Immuron executed a short-term funding agreement with Grandlodge for a principle amount of $1,000,000 (interest rate 13%), $750,000 (interest rate 15%) and $500,000 (interest rate 15%) respectively. The short-term funding is a cash advance against the anticipated refund Immuron will receive from the Australian Taxation Office under the Research and Development Income Tax Concession Incentive for the Company’s eligible R&D expenditure incurred for financial year of 2015, 2016 and 2017. Loan from December 2016, June 2016 and May 2017, plus applicable fees and interest, was repaid to Grandlodge on 10 February 2016, 2 December 2016 and 23 June 2017, respectively. Interest expense was approximately $57,000 and $31,000 for the years ended 30 June 2017 and 2016, respectively. In addition, the Company incurred approximately $35,000 of loan fees for the year ended 30 June 2016. Total paid by the Company to Grandlodge Pty Ltd during the year: — 1,329,007 1,043,863 At year end the Company owed Grandlodge Pty Ltd: — — 772,397 30 June 2018 30 June 2017 30 June 2016 Service rendered by Grandlodge Pty Ltd to Immuron Ltd: Grandlodge, and its associated entities, are marketing, warehousing and distribution logistics companies. Commencing on 1 June 2013, Grandlodge to provide warehousing, distribution and invoicing services for Immuron’s products for $70,000 per annum. These fees will be payable in new fully paid ordinary shares in Immuron Limited at a set price of $0.16 per share representing Immuron Limited’s share price at the commencement of the agreement. The shares to be issued to Grandlodge, or its associated entities, as compensation in lieu of cash payment for the services rendered under this agreement have been subject to the approval of Immuron shareholders at Company shareholder meetings held over the past 18 months. Grandlodge will also be reimbursed in cash for all reasonable costs and expenses incurred in accordance with their scope of works under the agreement, unless both parties agree to an alternative method of payment. The agreement is cancellable by either party upon providing the other party with 30 days written notice of the termination of the agreement. Service fees paid to Grandlodge Pty Ltd during the year through the issue of equity: 140,000 — 87,500 Total paid by the Company to Grandlodge Pty Ltd during the year: — — 87,500 At year end the Company owed Grandlodge Pty Ltd: 35,000 105,000 35,000 30 June 2018 30 June 2017 30 June 2016 Premises rental services received from Wattle Laboratories Pty Ltd to Immuron Limited: Wattle Laboratories Pty Ltd (Wattle) is an entity part-owned and operated by Immuron Directors Peter and Stephen Anastasiou. Commencing on 1 January 2016, Immuron executed a Lease Agreement with Wattle whereby Immuron will lease part of their Blackburn office facilities for Immuron’s operations at rental rate of $38,940 per annum, payable in monthly instalments. The rental agreement is subject to annual rental increases, and effective 1 January 2017, the annual rent was increased to $39,525. The lease is for a 3 year term with an additional 3 year option period. The lease is cancellable by either party upon 6 months written notice of termination of the agreement. Rental fees paid to Wattle Laboratories Pty Ltd during the year through the issue of equity: Total paid by the Company to Wattle Laboratories Pty Ltd during the year: 33,020 35,792 19,470 At year end the Company owed Wattle Laboratories Pty Ltd: — — 21,417 30 June 2018 30 June 2017 Service rendered by Great Accommodation Pty Ltd to Immuron Ltd: During the current financial year, the Company entered into a short-term loan arrangement with Great Accommodation Pty Ltd to fund on going R&D expenditure, for an amount of AUD $500,000 at an interest rate of 15% per annum and a AUD $15,000 establishment fee. The loan was repaid on 12 February 2018. Total paid by the Company to Great Accommodation Pty Ltd during the year: 520,342 — At year end the Company owed Great Accommodation Pty Ltd: — —

Financial Risk Management Obj_2

Financial Risk Management Objectives and Policies (Tables)	12 Months Ended
	Jun. 30, 2018
Financial Risk Management Objectives And Policies
Schedule of financial instruments	The Company’s financial instruments consist of cash, trade and other receivables, trade and other payables, borrowings and Convertible Notes: 30 June 2018 AUD$ 30 June 2017 AUD$ Cash 4,727,430 3,994,924 Trade receivables 492,276 1,768,237 Trade and other payables (689,326 ) (1,290,389 ) Borrowings (See Notes 13 and 20) — (139,864 ) Convertible notes — (226,000 )
Schedule of financial assets and liabilities are subject to foreign currency risk	The following financial assets and liabilities are subject to foreign currency risk: 30 June 2018 AUD$ 30 June 2017 AUD$ Cash (AUD/USD) 4,222,310 2,770,682 Trade and other receivable (AUD/USD) 161,138 126,207 Trade and other payables (AUD/USD) 57,667 502,651 Trade and other payables (AUD/CHF) — Trade and other payables (AUD/NZD) — Trade and other payables (AUD/ISL) 4,320 20,489
Schedule of exchange rates	The analysis shows that if the Company’s exposure to foreign currency risk was to fluctuate as disclosed below and all other variables had remained constant, then the foreign currency sensitivity impact on the Company’s loss after tax and equity would be as follows: Trade and Other Payables 30 June 2018 (Higher) / Lower AUD$ 30 June 2017 (Higher) / Lower AUD$ AUD / USD: 2018 +8.00% (2017: +8.00%) 6,343 35,186 AUD / USD: 2018 -8.00% (2017:-8.00%) (6,343 ) (35,186 ) AUD / ISL: 2018 +11.00% (2017: +11.00%) 302 2,254 AUD / ISL: 2018 -11.00% (2017: -11.00%) (302 ) (2,254 )
Schedule of trade and other receivables	The Company has analyzed its trade receivables (excluding R&D receivable) below: 0 - 30 days AUD$ 31 - 60 days AUD$ 61 - 90 days AUD$ 90 days + AUD$ Total AUD$ 2018 Trade receivables 250,806 122,890 106,494 11,986 492,276 2017 Trade receivables 173,248 33,731 419 62,727 270,125
Schedule of trade and other payables	The Company has analyzed its trade and other payables below: 0 - 30 days AUD$ 31 - 60 days AUD$ 61 - 90 days AUD$ 90 days + AUD$ Total AUD$ 2018 Trade and other payables and notes payable 216,938 — — — 216,938 2018 Borrowings (see Note 18 for repayment terms) — — — — — 2018 Convertible notes (note 13 for repayment terms) — — — — — 2017 Trade and other payables and notes payable 1,074,569 102,546 72,052 77,395 1,326,562 2017 Borrowings (see Note 18 for repayment terms) n/a n/a n/a n/a 139,864 2017 Convertible notes (note 13 for repayment terms) n/a n/a n/a n/a 226,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2017AUD ($)
Summary Of Significant Accounting Policies Details Abstract
Beginning balance	$ 1,128,117
- Issue
- Change in fair value (*)		[1]
- Repayments	(902,117)
Ending balance	$ 226,000	[2]
[1]	These amounts are recorded in the Finance Costs on the Statement of Profit or Loss and Other Comprehensive Income.
[2]	Convertible Notes: On 17 February 2016, the Company secured A$1,700,000 in funding with a New York-based Investment Fund. The facility was used to fund the immediate start of the clinical phase for IMM-529 in Clostridium difficile. The investment was structured in 3 tranches with a mix of equity financing and convertible securities according to the following: Tranche #1- A$100,000 private placement of securities plus a A$600,000 repayable Convertible Notes with A$78,000 finance charge; Tranche #2- 45 days after issuance of the tranche 1, the Company has the right to call a second Tranche as per Tranche 1 terms.Tranche #3 - by mutual consent, A$339,000 Face Value repayable Convertible Notes issuable on same terms as Tranche 1 and 2. Tranche #3 has not been issued as of the issuance date of the consolidated financial statements. The Convertible Notes were repayable monthly over an 18 month period with each repayment to be settled at Immurons discretion by: a) the issuance of new shares at a 10% discount to a 5 Day Volume Weighted Average Price (VWAP) over the 20 trading days immediately prior to a repayment due date; or b) cash repayment plus a 2.5% premium to the repayment amount. Immuron drew down Tranche 1 and Tranche 2 of the Convertible Note during fiscal year 2016. Immuron repaid A$902,117 in cash during the 2017 financial year and repaid A$77,217 in cash and A$150,666 in shares prior to 30 June 2016, as disclosed under Note 15. The balance of the outstanding convertible note as at 30 June 2017 was repaid during July 2017 and August 2017 with the liability being fully extinguished by 10 September 2017.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Jun. 30, 2018
Top of Range [Member] | Plant and Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	15 years
Top of Range [Member] | Computer Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	4 years
Top of Range [Member] | Fixtures and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	15 years
Bottom of Range [Member] | Plant and Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	3 years
Bottom of Range [Member] | Computer Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	2 years
Bottom of Range [Member] | Fixtures and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	3 years

Revenue and other income (Detai

Revenue and other income (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Revenue from Operating Activities
Sale of goods	$ 1,842,909	$ 1,396,197	$ 1,001,077
Total Revenue from Operating Activities	1,842,909	1,396,197	1,001,077
Other Income
Other income	40	30,672	14,010
Interest income	1,238	8,386	12,165
R&D tax concession refund	1,849,123	1,575,315	1,512,840
Other Income from Non-Operating Activities	1,850,401	1,614,373	1,539,015
Total Revenue and Other Income	$ 3,693,310	$ 3,010,570	$ 2,540,092

Expenses (Details)

Expenses (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Expenses
Consulting expenses			$ 46,775
Wages and salaries expenses	885,197	905,819	956,737
Superannuation and other employee related expenses	153,795	39,664	32,537
Director expenses	285,331	221,373	197,713
Share- based payments	59,975	522,665	1,606,275
Total Consulting, Employee and Director Expenses	1,384,298	1,689,521	2,840,037
Audit and accounting fees	222,973	146,007	62,825
Insurances	277,888	150,502	100,609
Foreign exchange (gain) / losses	(258,767)	238,985	217,904
Corporate administration costs	1,094,422	846,315	939,232
Total Corporate Administrative Costs	$ 1,336,516	$ 1,381,809	$ 1,320,570

Income Tax Benefit (Details)

Income Tax Benefit (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Income Tax Benefit
Profit from continuing operations before income tax expense	$ (3,010,929)	$ (6,804,154)	$ (7,068,767)
Tax at the Australian tax rate of 27.5% (2017 - 27.5%, 2016 – 30%)	(828,005)	(1,871,142)	(1,316,900)
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:
Non-deductible amounts associated with R&D rebates	(508,509)	(433,212)	(1,465,625)
Non-allowable expenses	796,398	1,681,990	402,618
Deferred tax assets relating to tax losses not recognized	540,116	622,364	2,379,907
Income tax expense

Income Tax Benefit (Details Nar

Income Tax Benefit (Details Narrative) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Income Tax Benefit
Tax losses	$ 35,299,886	$ 30,138,000
Deferred Tax Asset	$ 9,707,469	$ 8,287,950
Percentage of Income Tax Benefit	27.50%	27.50%

Key Management Personnel Comp_3

Key Management Personnel Compensation (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Key Management Personnel Compensation
Short-term employee benefits	$ 570,256	$ 681,666	$ 652,514
Post-employment benefits	32,087	25,947	26,004
Share-based payments	59,975	353,670	1,606,275
Total Key Management Personnel Compensation	$ 662,318	$ 1,061,283	$ 2,284,793

Loss per Share (Details)

Loss per Share (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Loss Per Share
Basic/Diluted loss per share (in cents)	$ 2.300	$ 6.400	$ 9.248
a) Net loss used in the calculation of basic and diluted loss per share	$ (3,010,929)	$ (6,804,154)	$ (7,068,767)
b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share	133,660,556	105,866,110	76,435,993	[1]
[1]	This amount includes 182,169 of weighted average shares for ordinary shares in relation to the A$4,511,378 received in capital raising that was not issued as of 30 June 2016.

Cash (Details)

Cash (Details) - AUD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Cash at Bank and in hand:
Cash at bank and in hand	$ 4,727,430	$ 3,994,924
Total Cash	$ 4,727,430	$ 3,994,924	$ 2,290,639

Cash (Details Narrative)

Cash (Details Narrative)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash and cash equivalents [abstract]
Interest rate on cash at bank	0.40%	1.00%

Trade and Other Receivables (De

Trade and Other Receivables (Details) - AUD ($)		Jun. 30, 2018	Jun. 30, 2017
Current
Trade receivables	[1]	$ 492,276	$ 270,125
Accrued income	[2]	1,191,029	1,498,112
Total Trade and Other Receivables		$ 1,683,305	$ 1,768,237
[1]	All trade receivables are non-interest bearing.
[2]	Primarily comprises of receivables from the Australian Tax Office in relation to R&D tax concession for the year.

Inventories (Details)

Inventories (Details) - AUD ($)	Jun. 30, 2018	Jun. 30, 2017
Current Inventory
Raw materials	$ 198,585	$ 1,793,882
Work in Progress	33,625	48,425
Finished goods	265,692	357,478
Prepaid inventory and supplies		136,342
Total Inventory	$ 497,902	$ 2,336,127

Inventories (Details 1)

Inventories (Details 1) - AUD ($)	Jun. 30, 2018	Jun. 30, 2017
Non-Current Inventory
Raw materials	$ 2,171,867
Total Non-Current Inventory	$ 2,171,867

Controlled Entities (Details)

Controlled Entities (Details)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Disclosure of subsidiaries [line items]
Country of Incorporation	Australia</font>" id="sjs-B4">&lt;font style="font: 10pt Times New Roman, Times, Serif">Australia&lt;/font>
Percentage of Ownership
Immuron Inc [Member]
Disclosure of subsidiaries [line items]
Country of Incorporation	USA</font>" id="sjs-B8">&lt;font style="font: 10pt Times New Roman, Times, Serif">USA&lt;/font>
Percentage of Ownership	100.00%	100.00%
Anadis EPS Pty Ltd [Member]
Disclosure of subsidiaries [line items]
Country of Incorporation	Australia</font>" id="sjs-B12">&lt;font style="font: 10pt Times New Roman, Times, Serif">Australia&lt;/font>
Percentage of Ownership	100.00%	100.00%
IMC Canada Ltd [Member]
Disclosure of subsidiaries [line items]
Country of Incorporation	Canada</p>" id="sjs-B16">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Canada&lt;/p>
Percentage of Ownership	100.00%	0.00%

Trade and Other Payables (Detai

Trade and Other Payables (Details) - AUD ($)	Jun. 30, 2018	Jun. 30, 2017
Current
Trade payables	$ 216,938	$ 699,530
Accrued expenses	435,280	568,988
Other payables	37,108	21,871
Total	$ 689,326	$ 1,290,389

Other Liabilities (Details)

Other Liabilities (Details) - AUD ($)		Jun. 30, 2018		Jun. 30, 2017		Jun. 30, 2016
Other Liabilities
Convertible Notes			[1]	$ 226,000	[1]	$ 1,128,117
Deferred Revenue	[2]			19,139
Borrowings	[3]			139,864
Total				$ 385,003
[1]	Convertible Notes: On 17 February 2016, the Company secured A$1,700,000 in funding with a New York-based Investment Fund. The facility was used to fund the immediate start of the clinical phase for IMM-529 in Clostridium difficile. The investment was structured in 3 tranches with a mix of equity financing and convertible securities according to the following: Tranche #1- A$100,000 private placement of securities plus a A$600,000 repayable Convertible Notes with A$78,000 finance charge; Tranche #2- 45 days after issuance of the tranche 1, the Company has the right to call a second Tranche as per Tranche 1 terms.Tranche #3 - by mutual consent, A$339,000 Face Value repayable Convertible Notes issuable on same terms as Tranche 1 and 2. Tranche #3 has not been issued as of the issuance date of the consolidated financial statements. The Convertible Notes were repayable monthly over an 18 month period with each repayment to be settled at Immurons discretion by: a) the issuance of new shares at a 10% discount to a 5 Day Volume Weighted Average Price (VWAP) over the 20 trading days immediately prior to a repayment due date; or b) cash repayment plus a 2.5% premium to the repayment amount. Immuron drew down Tranche 1 and Tranche 2 of the Convertible Note during fiscal year 2016. Immuron repaid A$902,117 in cash during the 2017 financial year and repaid A$77,217 in cash and A$150,666 in shares prior to 30 June 2016, as disclosed under Note 15. The balance of the outstanding convertible note as at 30 June 2017 was repaid during July 2017 and August 2017 with the liability being fully extinguished by 10 September 2017.
[2]	Deferred Revenue: This amount represents amounts billed by the Company for undelivered goods.
[3]	Borrowings: The Company has financed A$162,457 for its insurance policies during the year ended June 30, 2017. Principal and interest (A$8,561) is to be repaid monthly by Immuron over a 11-month term. During the financial year 2018, the outstanding borrowings were repaid by the Company.

Other Liabilities (Details Narr

Other Liabilities (Details Narrative)	Jun. 29, 2016AUD ($)	Feb. 17, 2016AUD ($)	Jun. 30, 2018	Jun. 30, 2017AUD ($)
Convertible Notes [Member]
Disclosure of financial liabilities [line items]
Convertible notes face value		$ 1,700,000
Repayment of convertible debt	$ 77,217			$ 902,117
Repayment of debt term			18 month
Issuance of new shares discount price (in percent)			0.10
Volume of weighted average price			5 Day Volume Weighted Average Price (VWAP) over the 20 trading days immediately prior to a repayment due date
Cash repayment with premium (in percent)			0.025
Repayment of debt in shares amount	$ 150,666
Equity Financing and Convertible Securities [Member] | Private Placement [Member] | Tranche 1 [Member]
Disclosure of financial liabilities [line items]
Convertible notes face value		100,000
Repayment of convertible debt		600,000
Financing charges		$ 78,000
Equity Financing and Convertible Securities [Member] | Private Placement [Member] | Tranche 2 [Member]
Disclosure of financial liabilities [line items]
Issuance of tranche description		45 days after issuance of the tranche 1, the Company has the right to call a second Tranche as per Tranche 1 terms.
Equity Financing and Convertible Securities [Member] | Private Placement [Member] | Tranche 3 [Member]
Disclosure of financial liabilities [line items]
Repayment of convertible debt		$ 339,000

Other Liabilities (Details Na_2

Other Liabilities (Details Narrative 1) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure of detailed information about borrowings [line items]
Principal and interest amount repaid	$ 865,864	$ 2,191,593	$ 1,077,220
Insurance Policies [Member]
Disclosure of detailed information about borrowings [line items]
Amount Financed		162,457
Principal and interest amount repaid		$ 8,561
Borrowing term		11 month

Commitments and Contingencies_2

Commitments and Contingencies (Details)	Jun. 30, 2018AUD ($)
Lease commitments not recognized in the financial statements:
Total	$ 19,470
Not Later Than 12 Months [Member]
Lease commitments not recognized in the financial statements:
Total	19,470
Between 1 And 5 Years [Member]
Lease commitments not recognized in the financial statements:
Total

Commitments and Contingencies_3

Commitments and Contingencies (Details Narrative) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Commitments And Contingencies
Rental expenses	$ 38,917	$ 46,082	$ 25,501
Discription of lease term	<font style="font: 10pt Times New Roman, Times, Serif">The property lease is a non-cancellable lease with a 3 year term, with rent payable monthly in advance. The minimum lease payments shall be increased by CPI per annum. An option exists to renew the lease at the end of the 3 year term for an additional term of 3 years. The current 3 year lease period expires in December 2018.</font></p>" id="sjs-B5">&lt;p style="font: 10pt Times New Roman, Times, Serif">&lt;font style="font: 10pt Times New Roman, Times, Serif">The property lease is a non-cancellable lease with a 3 year term, with rent payable monthly in advance. The minimum lease payments shall be increased by CPI per annum. An option exists to renew the lease at the end of the 3 year term for an additional term of 3 years. The current 3 year lease period expires in December 2018.&lt;/font>&lt;/p>

Contributed Equity (Details)

Contributed Equity (Details) - AUD ($)		Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Contributed Equity
Beginning balance (in shares)		130,041,417	80,099,646	74,964,232
Shares issued during the year (in shares)		14,736,789	49,941,771	5,135,414
Cancellation of shares (in shares)		(2,000,000)
Movement to Retained Earnings (in shares)
Total Contributed Equity (in shares)		142,778,206	130,041,417	80,099,646
Balance at beginning of year		$ 53,632,995	$ 45,633,354	$ 40,335,347
Shares issued during the year		5,472,200	9,965,323	1,721,789
Shares to be issued	[1]			4,511,378
Transactions costs		(733,152)	(2,037,557)	(135,160)
Treasury shares				(800,000)
Movement to Retained Earnings			71,875
Total Contributed Equity		$ 58,372,043	$ 53,632,995	$ 45,633,354
[1]	As at 30 June 2016, the Company was committed to issue 18,045,512 ordinary shares in relation to the A$4,511,378 received in capital raising.

Contributed Equity (Details 1)

Contributed Equity (Details 1) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Contributed Equity
Issue of Equity for the repayment of Sea Otter 16th payment of Convertible Note (in shares)	399,045
Issue of Equity for the repayment of Sea Otter 16th payment of Convertible Note	$ 75,333
Issue of Equity for the repayment of Sea Otter 16th payment of Convertible Note (in dollars per share)	$ 0.19
Issue of Shares to Grandlodge (in shares)	875,000
Issue of Shares to Grandlodge	$ 140,000
Issue of Shares to Grandlodge (in dollars per share)	$ 0.16
Private Placement to US Investment Fund (in shares)	13,162,744
Private Placement to US Investment Fund	$ 5,161,585
Private Placement to US Investment Fund (in dollars per share)	$ 0.39
Exercise of NASDAQ Warrants (IMRNW) (in shares)	300,000
Exercise of NASDAQ Warrants (IMRNW)	$ 95,282
Exercise of NASDAQ Warrants (IMRNW) (in dollars per share)	$ 0.32
Total 2018 Movement	14,736,789	49,941,771
Total 2018 Movement	$ 5,472,200	$ 9,965,323	$ 6,233,167

Contributed Equity (Details 2)

Contributed Equity (Details 2) - AUD ($)		12 Months Ended
		Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2016
Contributed Equity
Right issue (in shares)	[1]	18,045,512
Right issue (in shares)		3,275,466
Right issue to oversubscribes and private placement (in shares)		3,968,916
Shares under ESOP - for 6 months service (vesting monthly) (in shares)		251,877
Shares issued on NASDAQ (equivalent to 610,000 ADSs) (in shares)	[2]	24,400,000
Total 2017 Movement (in shares)		49,941,771	14,736,789
Right issue (in per shares)	[1]
Right issue (in per shares)		0.25
Right issue to oversubscribes and private placement (in per shares)		0.25
Shares under ESOP - for 6 months service (vesting monthly) (in per shares)		0.245
Shares issued on NASDAQ (equivalent to 610,000 ADSs) (in per shares)	[2]	$ 0.332
Right issue	[1]
Right issue		818,867
Right issue to oversubscribes and private placement		992,229
Shares under ESOP - for 6 months service (vesting monthly)		61,710
Shares issued on NASDAQ (equivalent to 610,000 ADSs)	[2]	8,092,517
Total 2017 Movement		$ 9,965,323	$ 5,472,200	$ 6,233,167
[1]	As at 30 June 2016, the Company was committed to issue 18,045,512 of ordinary shares in relation to the A$4,511,378 received in capital raising. These shares were subsequently issued to respective holders on 7 July 2016. 2,418,129 of these new fully paid ordinary shares were issued to Grandlodge on the same terms and conditions as all other subscribers.
[2]	Grandlodge participated in our NASDAQ IPO and acquired 32,707 ADRs and 32,707 Warrants.

Contributed Equity (Details 3)

Contributed Equity (Details 3) - AUD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2018	Jun. 30, 2017
Contributed Equity
Exercise of IMCAI Unlisted Options (in shares)	218,750
Exercise of IMCAI Unlisted Options (in shares)	93,750
Exercise of IMCAI Unlisted Options by Grandlodge (in shares)	556,000
Exercise of IMCAI Unlisted Options (in shares)	41,666
Issue of Shares in lieu of cash payment for services as per Resolution 4 of the Annual General Meeting (AGM) held on 25 Nov 2015 (in shares)	546,875
Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016 (in shares)	294,118
Issue of fully paid escrow shares as security for any repayment default of the Convertible Loan in accordance with executed funding agreement with a New York based Investment fund provider and announced to the ASX on 17 Feb 2016 (in shares)	2,000,000
Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016 (in shares)	326,797
First repayment of Convertible Notes Security in accordance with executed funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016 (in shares)	241,764
Exercise of IMCAI Unlisted Options (in shares)	150,000
Second repayment of Convertible Notes Security in accordance with executed funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016 (in shares)	265,694
Issue of Shares in lieu of cash payment for services received (in shares)	400,000
Shares to be Issued from Capital Raising as at 30 June 2016 (in shares)
Total 2016 Movement (in shares)	5,135,414
Exercise of IMCAI Unlisted Options (in per shares)	$ 0.376
Exercise of IMCAI Unlisted Options (in per shares)	0.376
Exercise of IMCAI Unlisted Options by Grandlodge (in per shares)	0.376
Exercise of IMCAI Unlisted Options (in per shares)	0.376
Issue of Shares in lieu of cash payment for services as per Resolution 4 of the Annual General Meeting (AGM) held on 25 Nov 2015 (in per shares)	0.16
Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016 (in per shares)	0.34
Issue of fully paid escrow shares as security for any repayment default of the Convertible Loan in accordance with executed funding agreement with a New York based Investment fund provider and announced to the ASX on 17 Feb 2016 (in per shares)	0.4
Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016 (in per shares)	0.306
First repayment of Convertible Notes Security in accordance with executed funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016 (in per shares)	0.312
Exercise of IMCAI Unlisted Options (in per shares)	0.276
Second repayment of Convertible Notes Security in accordance with executed funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016 (in per shares)	0.284
Issue of Shares in lieu of cash payment for services received (in per shares)	0.25
Shares to be Issued from Capital Raising as at 30 June 2016 (in per shares)
Exercise of IMCAI Unlisted Options	$ 82,250
Exercise of IMCAI Unlisted Options	35,250
Exercise of IMCAI Unlisted Options by Grandlodge	209,056
Exercise of IMCAI Unlisted Options	15,667
Issue of Shares in lieu of cash payment for services as per Resolution 4 of the Annual General Meeting (AGM) held on 25 Nov 2015	87,500
Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016	100,000
Issue of fully paid escrow shares as security for any repayment default of the Convertible Loan in accordance with executed funding agreement with a New York based Investment fund provider and announced to the ASX on 17 Feb 2016	800,000
Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016	100,000
First repayment of Convertible Notes Security in accordance with executed funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016	75,333
Exercise of IMCAI Unlisted Options	41,400
Second repayment of Convertible Notes Security in accordance with executed funding agreement with a New York based investment fund provider announced to the ASX on 17 Feb 2016	75,333
Issue of Shares in lieu of cash payment for services received	100,000
Shares to be Issued from Capital Raising as at 30 June 2016	4,511,378
Total 2016 Movement	$ 6,233,167	$ 5,472,200	$ 9,965,323

Reserves (Details)

Reserves (Details) - AUD ($)		12 Months Ended
		Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure of reserves within equity [line items]
Beginning balance		80,099,646	74,964,232
Ending balance		130,041,417	80,099,646	74,964,232
Options Over Fully Paid Ordinary Shares [Member]
Disclosure of reserves within equity [line items]
Beginning balance		63,690,523	9,937,629	7,188,676
Capital consolidation
Options issued during the year		8,424,157	56,002,894	7,425,532
Granted options to be issued	[1]
Options exercised during the year		(300,000)		(1,060,166)
Expense of vested options
Lapse of unexercised options		(465,500)	(2,250,000)	(3,616,413)
Ending balance		71,349,180	63,690,523	9,937,629
Beginning balance		$ 2,434,135	$ 2,132,301	$ 560,646
Capital consolidation
Options issued during the year		156,392	136,784	285,600
Granted options to be issued	[1]
Options exercised during the year				(71,875)
Expense of vested options		59,975	333,950	1,606,275
Lapse of unexercised options		(463)	(168,900)	(248,345)
Ending balance		$ 2,650,039	$ 2,434,135	$ 2,132,301
[1]	On 9 December 2016, the Company issued 1 million options exercisable at A$0.50 per option expiring on April 1, 2017 to an employee under the Company's ESOP following the successful completion of the related milestone pertaining to a minimum recruitment of 100 patients into the Company's NASH Phase 2 clinical trial.

Reserves (Details 1)

Reserves (Details 1) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure of reserves within equity [line items]
Beginning balance	80,099,646	74,964,232
Ending balance	130,041,417	80,099,646	74,964,232
Foreign Currency Translation Reserve [Member]
Disclosure of reserves within equity [line items]
Movement during the year
Ending balance
Total Reserves	63,690,523	63,690,523	9,937,629
Beginning balance	$ 36,282	$ (3,735)	$ (12,581)
Movement during the year	(79,599)	40,017	8,846
Ending balance	(43,317)	36,282	(3,735)
Total Reserves	$ 2,606,722	$ 2,470,417	$ 2,128,566

Reserves (Details 2)

Reserves (Details 2) - AUD ($)		12 Months Ended
		Jun. 30, 2018	Jun. 30, 2017		Jun. 30, 2016
Options Over Fully Paid Ordinary Shares [Member]
Disclosure of classes of share capital [line items]
No of shares		8,424,157	56,002,894		7,425,532
No of shares, value		$ 156,392	$ 136,784		$ 285,600
No of shares
No of shares	[1]
Right issue [Member]
Disclosure of classes of share capital [line items]
Date		Mar. 15, 2018	Jul. 7, 2016
Details		Issue of options- Free-attaching 3 options for every 5 new shares as a part of the capital raise	Right issue
No of shares		7,897,647	18,045,512	[2]
Issue price
No of shares, value
Right issue [Member]
Disclosure of classes of share capital [line items]
Date		Mar. 15, 2018	Jul. 7, 2016
Details		Issue of options - Broker shares as part of placement fee	Right issue
No of shares		526,510	3,275,466
Issue price		$ 0.3
No of shares, value		$ 156,392
Right issue [Member]
Disclosure of classes of share capital [line items]
Date			Sep. 29, 2016
Details			Right issue to oversubscribes and private placement
No of shares			3,968,916
Right issue [Member]
Disclosure of classes of share capital [line items]
Date			Dec. 9, 2016
Details			Unlisted options in lieu of services
No of shares			200,000
Issue price			$ 0.143
No of shares, value			$ 28,620
Right issue [Member]
Disclosure of classes of share capital [line items]
Date			Jun. 9, 2017
Details			Options issued to cover equivalent of 610,000 warrants on issue with NASDAQ
No of shares			24,400,000
Issue price			$ 0.00033
No of shares, value			$ 8,101
Right issue [Member]
Disclosure of classes of share capital [line items]
Date			Jun. 9, 2017
Details			Options issued to cover equivalent of 35,075 warrants on issue with NASDAQ
No of shares			1,403,000
Issue price			$ 0.00033
No of shares, value			$ 463
Right issue [Member]
Disclosure of classes of share capital [line items]
Date			Jun. 13, 2017
Details			Options issued to cover equivalent of 91,500 warrants on issue with NASDAQ
No of shares			3,660,000
Issue price			$ 0.00033
No of shares, value			$ 1,215
Right issue [Member]
Disclosure of classes of share capital [line items]
Date			Jun. 22, 2017
Details			Unlisted options in lieu of services
No of shares			1,050,000
Issue price			$ 0.094
No of shares, value			$ 98,385
Right issue [Member]
Disclosure of classes of share capital [line items]
Date					Nov. 27, 2015
Details					Issue of Unlisted Options in lieu of cash payment for additional services as per Resolution 5A - 5D of the AGM held on 25 Nov 2015
No of shares					6,000,000
No of shares, value					$ 1,606,275
Right issue [Member]
Disclosure of classes of share capital [line items]
Date					Feb. 18, 2016
Details					Issue in accordance with executed funding agreement with a New York based Investment fund provider announced to the ASX on 17 Feb 2016
No of shares					1,000,000
Issue price					$ 0.186
No of shares, value					$ 185,600
Right issue [Member]
Disclosure of classes of share capital [line items]
Date					May 31, 2016
Details					Issue of Unlisted Options in lieu of cash payment for services received
No of shares					425,532
Issue price					$ 0.235
No of shares, value					$ 100,000
[1]	On 9 December 2016, the Company issued 1 million options exercisable at A$0.50 per option expiring on April 1, 2017 to an employee under the Company's ESOP following the successful completion of the related milestone pertaining to a minimum recruitment of 100 patients into the Company's NASH Phase 2 clinical trial.
[2]	As of 30 June 2016, the Company was committed to issue 18,045,512 options in relation to the A$4,511,378 received in capital raising. These options were subsequently issued to respective holders on 7 July 2016. 2,418,129 of these options were issued to Grandlodge on the same terms and conditions as all other subscribers.

Segments Reporting (Details)

Segments Reporting (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Segment Revenue & Other income
Revenue from external customers	$ 1,842,909	$ 1,396,197	$ 1,001,077
R&D tax concession refund	1,850,361	1,575,315	1,512,840
Interest income	1,238	8,386	12,165
Other income	40	30,672	14,010
Total Segment Revenues & Other income	3,693,310	3,010,570	2,540,092
Segment Expenses
Depreciation	(5,047)	(4,922)	(3,892)
Finance costs	(18,857)	(24,483)	(156,000)
Share-based payments	(59,975)	(522,665)	(2,079,375)
Other operating expenses	(6,620,360)	(9,262,654)	(7,369,592)
Total Segment Expenses	(6,704,239)	(9,814,724)	(9,608,859)
Income Tax Expenses
(Loss)/Profit for the Period	(3,010,929)	(6,804,154)	(7,068,767)
Assets
Segment assets	9,242,688	8,286,491	8,827,484
Total Assets	9,242,688	8,286,491	8,827,484
Liabilities
Segment liabilities	(803,338)	(1,711,565)	(3,886,921)
Total Liabilities	(803,338)	(1,711,565)	(3,886,921)
Research And Development [Member]
Segment Revenue & Other income
Revenue from external customers
R&D tax concession refund	1,849,123	1,575,315	1,512,840
Interest income
Other income		25,000
Total Segment Revenues & Other income	1,849,123	1,600,315	1,512,840
Segment Expenses
Depreciation
Finance costs
Share-based payments		(188,481)
Other operating expenses	(2,257,224)	(4,805,874)	(3,623,961)
Total Segment Expenses	(2,257,224)	(4,994,355)	(3,623,961)
Income Tax Expenses
(Loss)/Profit for the Period	(408,101)	(3,394,040)	(2,111,121)
Assets
Segment assets	1,191,029	1,498,112	1,512,840
Total Assets	1,191,029	1,498,112	1,512,840
Liabilities
Segment liabilities	(174,434)	(514,326)	(769,434)
Total Liabilities	(174,434)	(514,326)	(769,434)
HyperImmune Products [Member]
Segment Revenue & Other income
Revenue from external customers	1,842,909	1,396,197	1,001,077
R&D tax concession refund
Interest income
Other income	40	5,672	10,200
Total Segment Revenues & Other income	1,842,949	1,401,869	1,011,277
Segment Expenses
Depreciation
Finance costs
Share-based payments
Other operating expenses	(832,661)	(1,017,169)	(570,183)
Total Segment Expenses	(832,661)	(1,017,169)	(570,183)
Income Tax Expenses
(Loss)/Profit for the Period	1,010,288	384,700	441,094
Assets
Segment assets	3,162,045	2,585,755	2,318,860
Total Assets	3,162,045	2,585,755	2,318,860
Liabilities
Segment liabilities	(26,009)	(330,218)	(538,806)
Total Liabilities	(26,009)	(330,218)	(538,806)
Unallocated Corporate [Member]
Segment Revenue & Other income
Revenue from external customers
R&D tax concession refund	1,238
Interest income		8,386	12,165
Other income			3,810
Total Segment Revenues & Other income	1,238	8,386	15,975
Segment Expenses
Depreciation	(5,047)	(4,922)	(3,892)
Finance costs	(18,857)	(24,483)	(156,000)
Share-based payments	(59,975)	(334,184)	(2,079,375)
Other operating expenses	(3,530,475)	(3,439,611)	(3,175,448)
Total Segment Expenses	(3,614,354)	(3,803,200)	(5,414,715)
Income Tax Expenses
(Loss)/Profit for the Period	(3,613,116)	(3,794,814)	(5,398,740)
Assets
Segment assets	4,889,614	4,202,624	4,995,784
Total Assets	4,889,614	4,202,624	4,995,784
Liabilities
Segment liabilities	(602,895)	(867,021)	(2,578,681)
Total Liabilities	$ (602,895)	$ (867,021)	$ (2,578,681)

Segments Reporting (Details 1)

Segments Reporting (Details 1)	12 Months Ended
	Jun. 30, 2018		Jun. 30, 2017	Jun. 30, 2016
Customer A [Member]
Disclosure of operating segments [line items]
Percentage of total revenue for major customers	31.00%		13.00%	16.00%
Customer B [Member]
Disclosure of operating segments [line items]
Percentage of total revenue for major customers	25.00%		34.00%	43.00%
Customer C [Member]
Disclosure of operating segments [line items]
Percentage of total revenue for major customers	12.00%		15.00%	22.00%
Customer D [Member]
Disclosure of operating segments [line items]
Percentage of total revenue for major customers	10.00%		15.00%		[1]
Customer E [Member]
Disclosure of operating segments [line items]
Percentage of total revenue for major customers		[1]	10.00%		[1]
[1]	Less than 10% of revenue for the respective year.

Segments Reporting (Details Nar

Segments Reporting (Details Narrative) - Segment	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure of operating segments [line items]
Number of segment		3
HyperImmune Products [Member] | AUSTRALIA
Disclosure of operating segments [line items]
Percentage of total revenue for major customers	62.00%	64.00%	78.00%
HyperImmune Products [Member] | CANADA
Disclosure of operating segments [line items]
Percentage of total revenue for major customers	1.00%	10.00%	4.00%
HyperImmune Products [Member] | UNITED STATES
Disclosure of operating segments [line items]
Percentage of total revenue for major customers	37.00%	26.00%	18.00%

Cash Flow Information (Details)

Cash Flow Information (Details) - AUD ($)		12 Months Ended
		Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Cash Flow Information
Loss for the Period		$ (3,010,929)	$ (6,804,154)	$ (7,068,767)
Non-Cash
Add depreciation expense		5,047	4,922	3,892
Add change in fair value and interest accrued on borrowings			8,561	178,401
Add back equity issued for non-cash consideration	[1]			187,500
Add back share based payments expense		242,950	522,665	1,891,875
Changes in Working Capital
Add decreases / (increases) in current trade and other receivables		84,932	7,396	(84,004)
Add decreases / (increases) in other current assets		26,561	69,034	(30,015)
Add (increases) in inventory		(333,642)	(280,060)	(909,800)
Add (decreases) / increases in current trade and other payables and deferred revenue		(620,202)	(559,452)	672,582
Add (decrease) increase in provisions		77,839
Total		$ (3,527,444)	$ (7,031,088)	$ (5,158,336)
[1]	The cost of A$187,500 relates to issue of shares worth A$87,500 in lieu of cash payments for services to Advanced Clinical Systems International as per resolution 4 of the AGM held on 25 November 2015. Additionally, shares worth A$100,000 were issued to The CFO Solution in lieu of services on 31 May 2016.

Cash Flow Information (Details

Cash Flow Information (Details Narrative) - AUD ($)		12 Months Ended
		Jun. 30, 2016	Jun. 30, 2017
Cash Flow Information
Subscription receivables	[1]	$ 2,612,139
Unpaid recognised expenses		$ 114,861
Financed insurance policies as borrowings			$ 162,457
[1]	Represents uncleared funds from the Capital Raising as at 30 June 2016. Funds were received on 7 July 2016 upon the issuance of shares.

Share-based Payments (Details)

Share-based Payments (Details) - ESOP [Member]	12 Months Ended
	Jun. 30, 2018shares$ / shares	Jun. 30, 2017shares$ / shares	Jun. 30, 2016shares$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding beginning balance | shares	1,312,500	1,062,500	1,856,150
Options capital consolidation | shares
Options granted during the year | shares		1,250,000
Granted options to be issued | shares
Options exercised | shares			(150,000)
Lapse of unexercised options | shares		(1,000,000)	(643,650)
Outstanding ending balance | shares	1,312,500	1,312,500	1,062,500
Options Exercisable ending balance | shares	1,312,500	1,312,500	62,500
Outstanding beginning balance | $ / shares	$ 0.550	$ 1.562	$ 0.440
Options capital consolidation | $ / shares
Options granted during the year | $ / shares		0.500
Granted options to be issued | $ / shares
Options exercised | $ / shares			0.276
Lapse of unexercised options | $ / shares		0.500	0.276
Outstanding ending balance | $ / shares	0.550	0.550	1.562
Options Exercisable ending balance | $ / shares	$ 0.550	$ 0.550	$ 1.556

Share-based Payments (Details 1

Share-based Payments (Details 1) - Directors [member]	12 Months Ended
	Jun. 30, 2018shares$ / shares	Jun. 30, 2017shares$ / shares	Jun. 30, 2016shares$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding beginning balance | shares	6,000,000	7,000,000	1,000,000
Options capital consolidation | shares
Options granted during the year | shares			6,000,000
Lapse of unexercised options | shares		(1,000,000)
Outstanding ending balance | shares	6,000,000	6,000,000	7,000,000
Options Exercisable ending balance | shares	6,000,000	5,000,000	1,000,000
Outstanding beginning balance | $ / shares	$ 0.500	$ 0.494	$ 0.456
Options capital consolidation | $ / shares
Options granted during the year | $ / shares			0.500
Lapse of unexercised options | $ / shares		0.460
Outstanding ending balance | $ / shares	0.500	0.500	0.494
Options Exercisable ending balance | $ / shares	$ 0.500	$ 0.500	$ 0.456

Share-based Payments (Details 2

Share-based Payments (Details 2) - Warrants [Member]	12 Months Ended
	Jun. 30, 2018shares$ / shares	Jun. 30, 2017shares$ / shares	Jun. 30, 2016shares$ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding beginning balance | shares	56,378,023	1,875,129	4,332,526
Options capital consolidation | shares
Options granted during the year | shares	8,424,157	54,752,894	1,425,532
Options exercised | shares	(300,000)		(910,166)
Lapse of unexercised options | shares	(465,500)	(250,000)	(2,972,763)
Outstanding ending balance | shares	64,036,680	56,378,023	1,875,129
Options Exercisable ending balance | shares	64,036,680	56,378,023	1,875,129
Outstanding beginning balance | $ / shares	$ 0.440	$ 0.561	$ 0.400
Options capital consolidation | $ / shares
Options granted during the year | $ / shares	0.470	0.430	0.549
Options exercised | $ / shares			0.376
Lapse of unexercised options | $ / shares	1.550	0.460	0.376
Outstanding ending balance | $ / shares	0.470	0.440	0.561
Options Exercisable ending balance | $ / shares	$ 0.470	$ 0.440	$ 0.561

Share-based Payments (Details 3

Share-based Payments (Details 3)	12 Months Ended
	Jun. 30, 2018shares$ / shares
Vesting Period One [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Jun. 29, 2012
Number of Options | shares	14,493
Expiry Date	Nov. 30, 2021
Exercise Price | $ / shares	$ 1.944
Vesting Period Two [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Jun. 29, 2012
Number of Options | shares	29,668
Expiry Date	Jan. 17, 2022
Exercise Price | $ / shares	$ 1.876
Vesting Period Three [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Mar. 3, 2014
Number of Options | shares	15,380
Expiry Date	Feb. 28, 2019
Exercise Price | $ / shares	$ 1.892
Vesting Period Four [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	May 29, 2014
Number of Options | shares	140,056
Expiry Date	May 28, 2019
Exercise Price | $ / shares	$ 0.3
Vesting Period Five [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Nov. 27, 2015
Number of Options | shares	6,000,000
Vesting Conditions	See below
Expiry Date	Nov. 27, 2019
Exercise Price | $ / shares	$ 0.5
Vesting Period Six [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Feb. 18, 2016
Number of Options | shares	1,000,000
Expiry Date	Feb. 24, 2019
Exercise Price | $ / shares	$ 0.57
Vesting Period Seven [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	May 31, 2016
Number of Options | shares	425,532
Expiry Date	Nov. 27, 2019
Exercise Price | $ / shares	$ 0.5
Vesting Period Eight [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Jul. 7, 2016
Number of Options | shares	25,289,894
Expiry Date	Nov. 30, 2019
Exercise Price | $ / shares	$ 0.55
Vesting Period Nine [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Dec. 9, 2016
Number of Options | shares	200,000
Expiry Date	Nov. 27, 2019
Exercise Price | $ / shares	$ 0.5
Vesting Period Ten [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Jun. 9, 2017
Number of Options | shares	24,400,000
Expiry Date	Jun. 13, 2022
Exercise Price | $ / shares	$ 0.326
Vesting Period Eleven [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Jun. 13, 2017
Number of Options | shares	3,660,000
Expiry Date	Jun. 13, 2022
Exercise Price | $ / shares	$ 0.326
Vesting Period Twelve [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Jun. 22, 2017
Number of Options | shares	1,050,000
Expiry Date	Oct. 1, 2018
Exercise Price | $ / shares	$ 0.5
Vesting Period Thirteen [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Jun. 22, 2017
Number of Options | shares	1,000,000
Expiry Date	Nov. 27, 2019
Exercise Price | $ / shares	$ 0.500
Vesting Period Fourteen [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Mar. 15, 2018
Number of Options | shares	7,897,647
Expiry Date	Mar. 15, 2023
Exercise Price | $ / shares	$ 0.468
Vesting Period Fifteen [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issue Date	Mar. 15, 2018
Number of Options | shares	526,510
Expiry Date	Mar. 15, 2023
Exercise Price | $ / shares	$ 0.585

Share-based Payments (Details 4

Share-based Payments (Details 4)	12 Months Ended
	Jun. 30, 2018$ / shares
November 2015 Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting date	Nov15
Dividend yield
Expected volatility	100.00%
Risk-free interest rate	2.11%
Expected life of option (years)	4 years
Option exercise price	$ 0.5
Weighted average share price at grant date	0.465
Value per option	$ 0.3186
February 2016 Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Dividend yield
Expected volatility	97.00%
Risk-free interest rate	1.73%
Expected life of option (years)	3 years
Option exercise price	$ 0.57
Weighted average share price at grant date	0.36
Value per option	$ 0.1856
May 2016 Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Dividend yield
Expected volatility	84.00%
Risk-free interest rate	2.11%
Expected life of option (years)	4 years
Option exercise price	$ 0.5
Weighted average share price at grant date	0.41
Value per option	$ 0.235
December 2016 Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Dividend yield
Expected volatility	100.00%
Risk-free interest rate	1.69%
Expected life of option (years)	3 years 2 months 1 day
Option exercise price	$ 0.5
Weighted average share price at grant date	0.285
Value per option	$ 0.1431
June 2017 Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Dividend yield
Expected volatility	100.00%
Risk-free interest rate	1.69%
Expected life of option (years)	1 year 3 months 29 days
Option exercise price	$ 0.5
Weighted average share price at grant date	0.315
Value per option	$ 0.0937

Share-based Payments (Details N

Share-based Payments (Details Narrative) - $ / shares	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average remaining contractual life (in year)	4 years 7 months 2 days	3 years 6 months 25 days
Warrants [Member] | Bottom of Range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	$ 0.30	$ 0.30
Warrants [Member] | Top of Range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	$ 1.94	$ 1.944
Directors [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average remaining contractual life (in year)	2 years 4 months 28 days	2 years 11 months 8 days
Exercise price	$ 0.50	$ 0.50
ESOP [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average remaining contractual life (in year)	1 year 4 months 20 days	1 year 4 months 14 days
ESOP [Member] | Bottom of Range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	$ 0.50	$ 0.50
ESOP [Member] | Top of Range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	$ 1.56	$ 1.56

Related Party Transactions (Det

Related Party Transactions (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Services rendered / Premises Rental services received:
Rental fees paid during the year through the issue of equity:	$ 38,917	$ 46,082	$ 25,501
Grandlodge Pty Ltd [Member] | Short-term Borrowings [Member]
Short-term Loan:
Total paid by the Company		1,329,007	1,043,863
At year end the Company owed			772,397
Services rendered / Premises Rental services received:
Service fees paid during the year through the issue of equity:	140,000		87,500
Total paid by the Company			87,500
At year end the Company owed:	35,000	105,000	35,000
Wattle Laboratories Pty Ltd [Member]
Services rendered / Premises Rental services received:
Rental fees paid during the year through the issue of equity:
Total paid by the Company	33,020	35,792	19,470
At year end the Company owed:			$ 21,417
Great Accommodation Pty Ltd [Member]
Services rendered / Premises Rental services received:
Total paid by the Company	520,342
At year end the Company owed:

Related Party Transactions (D_2

Related Party Transactions (Details Narrative) - AUD ($)	Jun. 01, 2013	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016	May 09, 2017	Jun. 06, 2016	Dec. 01, 2015
Disclosure of transactions between related parties [line items]
Rental expense		$ 38,917	$ 46,082	$ 25,501
Wattle Laboratories Pty Ltd [Member]
Disclosure of transactions between related parties [line items]
Rental expense
Short-term Funding Agreements [Member]
Disclosure of transactions between related parties [line items]
Warehousing, distribution and invoicing services	$ 70,000
share issued price per share (in dollars per share)	$ 0.16
Short-term Funding Agreements [Member] | Grandlodge Pty Ltd [Member]
Disclosure of transactions between related parties [line items]
Principal amount					$ 500,000	$ 750,000	$ 1,000,000
Interest rate					15.00%	15.00%	13.00%
Interest expense			57,000	31,000
Loan fees				35,000
Short-term Funding Agreements [Member] | Wattle Laboratories Pty Ltd [Member]
Disclosure of transactions between related parties [line items]
Rental expense			$ 39,525	$ 38,940
Lease term		3 years
Additional lease term		3 years
Short-term loan arrangement [Member] | Great Accommodation Pty Ltd [Member]
Disclosure of transactions between related parties [line items]
Principal amount		$ 500,000
Interest rate		15.00%
Establishment fee		$ 15,000
Loan maturity date		Feb. 12, 2018

Financial Risk Management Obj_3

Financial Risk Management Objectives and Policies (Details) - AUD ($)		Jun. 30, 2018		Jun. 30, 2017		Jun. 30, 2016
Financial Risk Management Objectives And Policies
Cash		$ 4,727,430		$ 3,994,924		$ 2,290,639
Trade receivables	[1]	492,276		270,125
Trade and other payables		689,326		1,290,389
Borrowings (See Notes 13 and 20)	[2]			(139,864)
Convertible notes			[3]	$ 226,000	[3]	$ 1,128,117
[1]	All trade receivables are non-interest bearing.
[2]	Borrowings: The Company has financed A$162,457 for its insurance policies during the year ended June 30, 2017. Principal and interest (A$8,561) is to be repaid monthly by Immuron over a 11-month term. During the financial year 2018, the outstanding borrowings were repaid by the Company.
[3]	Convertible Notes: On 17 February 2016, the Company secured A$1,700,000 in funding with a New York-based Investment Fund. The facility was used to fund the immediate start of the clinical phase for IMM-529 in Clostridium difficile. The investment was structured in 3 tranches with a mix of equity financing and convertible securities according to the following: Tranche #1- A$100,000 private placement of securities plus a A$600,000 repayable Convertible Notes with A$78,000 finance charge; Tranche #2- 45 days after issuance of the tranche 1, the Company has the right to call a second Tranche as per Tranche 1 terms.Tranche #3 - by mutual consent, A$339,000 Face Value repayable Convertible Notes issuable on same terms as Tranche 1 and 2. Tranche #3 has not been issued as of the issuance date of the consolidated financial statements. The Convertible Notes were repayable monthly over an 18 month period with each repayment to be settled at Immurons discretion by: a) the issuance of new shares at a 10% discount to a 5 Day Volume Weighted Average Price (VWAP) over the 20 trading days immediately prior to a repayment due date; or b) cash repayment plus a 2.5% premium to the repayment amount. Immuron drew down Tranche 1 and Tranche 2 of the Convertible Note during fiscal year 2016. Immuron repaid A$902,117 in cash during the 2017 financial year and repaid A$77,217 in cash and A$150,666 in shares prior to 30 June 2016, as disclosed under Note 15. The balance of the outstanding convertible note as at 30 June 2017 was repaid during July 2017 and August 2017 with the liability being fully extinguished by 10 September 2017.

Financial Risk Management Obj_4

Financial Risk Management Objectives and Policies (Details 1) - AUD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Disclosure of risk management strategy related to hedge accounting [line items]
Cash (AUD/USD)	$ 4,727,430	$ 3,994,924	$ 2,290,639
Trade and other receivable (AUD/USD)	1,683,305	1,768,237
Trade and other payables (AUD/USD)	689,326	1,290,389
Foreign Currency Risk [Member]
Disclosure of risk management strategy related to hedge accounting [line items]
Cash (AUD/USD)	4,222,310	2,770,682
Trade and other receivable (AUD/USD)	161,138	126,207
Trade and other payables (AUD/USD)	57,667	502,651
Trade and other payables (AUD/CHF)
Trade and other payables (AUD/NZD)
Trade and other payables (AUD/ISL)	$ 4,320	$ 20,489

Financial Risk Management Obj_5

Financial Risk Management Objectives and Policies (Details 2)	Jun. 30, 2018AUD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2018ILS (₪)	Jun. 30, 2017AUD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2017ILS (₪)
Disclosure of financial assets [line items]
Trade and Other Payables	$ 689,326			$ 1,290,389
Foreign Currency Risk [Member]
Disclosure of financial assets [line items]
Trade and Other Payables	$ 57,667			$ 502,651
Foreign Currency Risk [Member] | USD | Top of Range [Member]
Disclosure of financial assets [line items]
Trade and Other Payables		$ 6,343			$ 35,186
Exchange rate	0.08	0.08	0.08	0.08	0.08	0.08
Foreign Currency Risk [Member] | USD | Bottom of Range [Member]
Disclosure of financial assets [line items]
Trade and Other Payables		$ (6,343)			$ (35,186)
Exchange rate	(0.08)	(0.08)	(0.08)	(0.08)	(0.08)	(0.08)
Foreign Currency Risk [Member] | ILS | Top of Range [Member]
Disclosure of financial assets [line items]
Trade and Other Payables | ₪			₪ 302			₪ 2,254
Exchange rate	0.11	0.11	0.11	0.11	0.11	0.11
Foreign Currency Risk [Member] | ILS | Bottom of Range [Member]
Disclosure of financial assets [line items]
Trade and Other Payables | ₪			₪ (302)			₪ (2,254)
Exchange rate	(0.11)	(0.11)	(0.11)	(0.11)	(0.11)	(0.11)

Financial Risk Management Obj_6

Financial Risk Management Objectives and Policies (Details 3) - Trade Receivables [Member] - AUD ($)	Jun. 30, 2018	Jun. 30, 2017
Disclosure of financial assets [line items]
Financial assets	$ 492,276	$ 270,125
0 - 30 days [Member]
Disclosure of financial assets [line items]
Financial assets	250,806	173,248
31 - 60 days [Member]
Disclosure of financial assets [line items]
Financial assets	122,890	33,731
61 - 90 days [Member]
Disclosure of financial assets [line items]
Financial assets	106,494	419
90 days + [Member]
Disclosure of financial assets [line items]
Financial assets	$ 11,986	$ 62,727

Financial Risk Management Obj_7

Financial Risk Management Objectives and Policies (Details 4) - AUD ($)	Jun. 30, 2018	Jun. 30, 2017
Trade And Other Payables And Notes Payable [Member]
Disclosure of financial liabilities [line items]
Financial liabilities	$ 216,938	$ 1,326,562
Borrowings [Member]
Disclosure of financial liabilities [line items]
Financial liabilities		139,864
Convertible Notes [Member]
Disclosure of financial liabilities [line items]
Financial liabilities		226,000
0 - 30 days [Member] | Trade And Other Payables And Notes Payable [Member]
Disclosure of financial liabilities [line items]
Financial liabilities	216,938	1,074,569
0 - 30 days [Member] | Borrowings [Member]
Disclosure of financial liabilities [line items]
Financial liabilities
0 - 30 days [Member] | Convertible Notes [Member]
Disclosure of financial liabilities [line items]
Financial liabilities
31 - 60 days [Member] | Trade And Other Payables And Notes Payable [Member]
Disclosure of financial liabilities [line items]
Financial liabilities		102,546
31 - 60 days [Member] | Borrowings [Member]
Disclosure of financial liabilities [line items]
Financial liabilities
31 - 60 days [Member] | Convertible Notes [Member]
Disclosure of financial liabilities [line items]
Financial liabilities
61 - 90 days [Member] | Trade And Other Payables And Notes Payable [Member]
Disclosure of financial liabilities [line items]
Financial liabilities		72,052
61 - 90 days [Member] | Borrowings [Member]
Disclosure of financial liabilities [line items]
Financial liabilities
61 - 90 days [Member] | Convertible Notes [Member]
Disclosure of financial liabilities [line items]
Financial liabilities
90 days + [Member] | Trade And Other Payables And Notes Payable [Member]
Disclosure of financial liabilities [line items]
Financial liabilities		77,395
90 days + [Member] | Borrowings [Member]
Disclosure of financial liabilities [line items]
Financial liabilities
90 days + [Member] | Convertible Notes [Member]
Disclosure of financial liabilities [line items]
Financial liabilities

Events after the Reporting Da_2

Events after the Reporting Date (Details Narrative)	Jul. 02, 2018AUD ($)shares	Jun. 30, 2018AUD ($)	Jun. 30, 2017AUD ($)	Jun. 30, 2016AUD ($)
Disclosure of non-adjusting events after reporting period [line items]
Number of shares issued		$ 4,739,048	$ 7,927,766	$ 1,586,629
Dr Jerry Kanellos [Member] | Subsequent Event [Member]
Disclosure of non-adjusting events after reporting period [line items]
Number of shares issued	$ 1,000,000
Richard J Berman [Member] | Subsequent Event [Member]
Disclosure of non-adjusting events after reporting period [line items]
Number of options granted | shares	2,000,000